1,962 results on '"Quinn, Joseph"'
Search Results
2. Parkinsons disease variant detection and disclosure: PD GENEration, a North American study.
- Author
-
Cook, Lola, Verbrugge, Jennifer, Schwantes-An, Tae-Hwi, Schulze, Jeanine, Foroud, Tatiana, Hall, Anne, Marder, Karen, Mata, Ignacio, Mencacci, Niccolò, Nance, Martha, Schwarzschild, Michael, Simuni, Tanya, Bressman, Susan, Wills, Anne-Marie, Fernandez, Hubert, Litvan, Irene, Lyons, Kelly, Shill, Holly, Singer, Carlos, Tropea, Thomas, Vanegas Arroyave, Nora, Carbonell, Janfreisy, Cruz Vicioso, Rossy, Katus, Linn, Quinn, Joseph, Hodges, Priscila, Meng, Yan, Strom, Samuel, Blauwendraat, Cornelis, Lohmann, Katja, Casaceli, Cynthia, Rao, Shilpa, Ghosh Galvelis, Kamalini, Naito, Anna, Beck, James, and Alcalay, Roy
- Subjects
GBA1 ,LRRK2 ,Parkinson’s disease ,clinical trials ,genetic counselling ,genetic testing ,Humans ,Parkinson Disease ,Genetic Testing ,Male ,Female ,Glucosylceramidase ,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 ,alpha-Synuclein ,Aged ,Middle Aged ,Ubiquitin-Protein Ligases ,Protein Kinases ,Protein Deglycase DJ-1 ,Vesicular Transport Proteins ,North America ,Genetic Variation ,Genetic Predisposition to Disease ,Adult ,Disclosure ,Genetic Counseling ,Canada ,United States - Abstract
Variants in seven genes (LRRK2, GBA1, PRKN, SNCA, PINK1, PARK7 and VPS35) have been formally adjudicated as causal contributors to Parkinsons disease; however, individuals with Parkinsons disease are often unaware of their genetic status since clinical testing is infrequently offered. As a result, genetic information is not incorporated into clinical care, and variant-targeted precision medicine trials struggle to enrol people with Parkinsons disease. Understanding the yield of genetic testing using an established gene panel in a large, geographically diverse North American population would help patients, clinicians, clinical researchers, laboratories and insurers better understand the importance of genetics in approaching Parkinsons disease. PD GENEration is an ongoing multi-centre, observational study (NCT04057794, NCT04994015) offering genetic testing with results disclosure and genetic counselling to those in the US (including Puerto Rico), Canada and the Dominican Republic, through local clinical sites or remotely through self-enrolment. DNA samples are analysed by next-generation sequencing including deletion/duplication analysis (Fulgent Genetics) with targeted testing of seven major Parkinsons disease-related genes. Variants classified as pathogenic/likely pathogenic/risk variants are disclosed to all tested participants by either neurologists or genetic counsellors. Demographic and clinical features are collected at baseline visits. Between September 2019 and June 2023, the study enrolled 10 510 participants across >85 centres, with 8301 having received results. Participants were: 59% male; 86% White, 2% Asian, 4% Black/African American, 9% Hispanic/Latino; mean age 67.4 ± 10.8 years. Reportable genetic variants were observed in 13% of all participants, including 18% of participants with one or more high risk factors for a genetic aetiology: early onset (
- Published
- 2024
3. LATE-NC risk alleles (in TMEM106B, GRN, and ABCC9 genes) among persons with African ancestry.
- Author
-
Katsumata, Yuriko, Fardo, David W, Shade, Lincoln MP, Bowen, James D, Crane, Paul K, Jarvik, Gail P, Keene, C Dirk, Larson, Eric B, McCormick, Wayne C, McCurry, Susan M, Mukherjee, Shubhabrata, Kowall, Neil W, McKee, Ann C, Honig, Robert A, Lawrence, S, Vonsattel, Jean Paul, Williamson, Jennifer, Small, Scott, Burke, James R, Hulette, Christine M, Welsh-Bohmer, Kathleen A, Gearing, Marla, Lah, James J, Levey, Allan I, Wingo, Thomas S, Apostolova, Liana G, Farlow, Martin R, Ghetti, Bernardino, Saykin, Andrew J, Spina, Salvatore, Albert, Marilyn S, Lyketsos, Constantine G, Troncoso, Juan C, Frosch, Matthew P, Green, Robert C, Growdon, John H, Hyman, Bradley T, Tanzi, Rudolph E, Potter, Huntington, Dickson, Dennis W, Ertekin-Taner, Nilufer, Graff-Radford, Neill R, Parisi, Joseph E, Petersen, Ronald C, Duara, Ranjan, Buxbaum, Joseph D, Goate, Alison M, Sano, Mary, Masurkar, Arjun V, Wisniewski, Thomas, Bigio, Eileen H, Mesulam, Marsel, Weintraub, Sandra, Vassar, Robert, Kaye, Jeffrey A, Quinn, Joseph F, Woltjer, Randall L, Barnes, Lisa L, Bennett, David A, Schneider, Julie A, Yu, Lei, Henderson, Victor, Fallon, Kenneth B, Harrell, Lindy E, Marson, Daniel C, Roberson, Erik D, DeCarli, Charles, Jin, Lee-Way, Olichney, John M, Kim, Ronald, LaFerla, Frank M, Monuki, Edwin, Head, Elizabeth, Sultzer, David, Geschwind, Daniel H, Vinters, Harry V, Chesselet, Marie-Francoise, Galasko, Douglas R, Brewer, James B, Boxer, Adam, Karydas, Anna, Kramer, Joel H, Miller, Bruce L, Rosen, Howard J, Seeley, William W, Burns, Jeffrey M, Swerdlow, Russell H, Abner, Erin, Van Eldik, Linda J, Albin, Roger L, Lieberman, Andrew P, Paulson, Henry L, Arnold, Steven E, Trojanowski, John Q, Van Deerlin, Vivianna M, Hamilton, Ronald L, Kamboh, M Ilyas, Lopez, Oscar L, and Becker, James T
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Brain Disorders ,Neurodegenerative ,Alzheimer's Disease ,Acquired Cognitive Impairment ,Prevention ,Aging ,Minority Health ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Dementia ,Health Disparities ,Genetics ,2.1 Biological and endogenous factors ,Aetiology ,Humans ,Alleles ,Polymorphism ,Single Nucleotide ,Alzheimer Disease ,TDP-43 Proteinopathies ,Progranulins ,Membrane Proteins ,Nerve Tissue Proteins ,Sulfonylurea Receptors ,Alzheimer’s Disease Genetics Consortium ,KCNMB2 ,Diversity ,Epidemiology ,FTLD ,Genome-Wide Association Studies ,KATP ,Neurology & Neurosurgery ,Clinical sciences - Abstract
Limbic-predominant age-related TDP-43 encephalopathy (LATE) affects approximately one-third of older individuals and is associated with cognitive impairment. However, there is a highly incomplete understanding of the genetic determinants of LATE neuropathologic changes (LATE-NC) in diverse populations. The defining neuropathologic feature of LATE-NC is TDP-43 proteinopathy, often with comorbid hippocampal sclerosis (HS). In terms of genetic risk factors, LATE-NC and/or HS are associated with single nucleotide variants (SNVs) in 3 genes-TMEM106B (rs1990622), GRN (rs5848), and ABCC9 (rs1914361 and rs701478). We evaluated these 3 genes in convenience samples of individuals of African ancestry. The allele frequencies of the LATE-associated alleles were significantly different between persons of primarily African (versus European) ancestry: In persons of African ancestry, the risk-associated alleles for TMEM106B and ABCC9 were less frequent, whereas the risk allele in GRN was more frequent. We performed an exploratory analysis of data from African-American subjects processed by the Alzheimer's Disease Genomics Consortium, with a subset of African-American participants (n = 166) having corroborating neuropathologic data through the National Alzheimer's Coordinating Center (NACC). In this limited-size sample, the ABCC9/rs1914361 SNV was associated with HS pathology. More work is required concerning the genetic factors influencing non-Alzheimer disease pathology such as LATE-NC in diverse cohorts.
- Published
- 2023
4. Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers
- Author
-
Sandau, Ursula S., Wiedrick, Jack T., McFarland, Trevor J., Galasko, Douglas R., Fanning, Zoe, Quinn, Joseph F., and Saugstad, Julie A.
- Published
- 2024
- Full Text
- View/download PDF
5. Research Priorities of Individuals and Caregivers With Lewy Body Dementia: A Web-based Survey.
- Author
-
Schwilk, Chris, Fleisher, Jori, Duda, John, Shill, Holly, Paulson, Henry, Stacy, Kelly, Wood, Julia, Corsentino, Pamela, Sha, Sharon, Irwin, David, Quinn, Joseph, Goldman, Jennifer, Amodeo, Katherine, Taylor, John-Paul, Boeve, Bradley, Armstrong, Melissa, Holden, Samantha, Bedenfield, Noheli, Taylor, Angela, Litvan, Irene, and Bayram, Ece
- Subjects
Humans ,Lewy Body Disease ,Caregivers ,Surveys and Questionnaires ,Internet - Abstract
INTRODUCTION: Lewy body dementia (LBD) is common, yet under-recognized and under-researched. To plan studies with the highest impact, engagement of the community personally affected by these conditions is essential. METHODS: A web-based survey of people living with LBD and current and former caregivers of people with LBD queried research priorities through forced ranking and exploration of burden of LBD symptoms. Specific caregiving needs in LBD and perceptions of research participation were also investigated. RESULTS: Between April 7, 2021 and July 1, 2021, 984 responses were recorded. Top research priorities included disease-modifying therapies and improved disease detection and staging. People with LBD were interested in pathophysiology and more bothered by motor symptoms; caregivers were interested in risk factors and symptomatic therapies and more bothered by neuropsychiatric symptoms. Few available LBD treatments and resources were rated as helpful, and many valuable services were never received. Previous participation in LBD research was infrequent, but interest was high. DISCUSSION: People with LBD and caregivers highlighted the need for research across all aspects of LBD, from pathophysiology and disease modification to prognosis, education, symptomatic treatments, and caregiver support. Funders should increase support for all aspects of LBD research to target the many needs identified by individuals and families living with LBD.
- Published
- 2023
6. A data‐driven examination of apathy and depressive symptoms in dementia with independent replication
- Author
-
Da Silva, Miguel Vasconcelos, Melendez‐Torres, Gerardo Javier, Ismail, Zahinoor, Testad, Ingelin, Ballard, Clive, Creese, Byron, Weiner, Michael, Aisen, Paul, Petersen, Ronald, Jack, Clifford R, Jagust, William, Trojanowki, John Q, Toga, Arthur W, Beckett, Laurel, Green, Robert C, Saykin, Andrew J, Morris, John, Shaw, Leslie M, Liu, Enchi, Montine, Tom, Thomas, Ronald G, Donohue, Michael, Walter, Sarah, Gessert, Devon, Sather, Tamie, Jiminez, Gus, Harvey, Danielle, Bernstein, Matthew, Fox, Nick, Thompson, Paul, Schuff, Norbert, DeCArli, Charles, Borowski, Bret, Gunter, Jeff, Senjem, Matt, Vemuri, Prashanthi, Jones, David, Kantarci, Kejal, Ward, Chad, Koeppe, Robert A, Foster, Norm, Reiman, Eric M, Chen, Kewei, Mathis, Chet, Landau, Susan, Cairns, Nigel J, Householder, Erin, Reinwald, Lisa Taylor, Lee, Virginia, Korecka, Magdalena, Figurski, Michal, Crawford, Karen, Neu, Scott, Foroud, Tatiana M, Potkin, Steven, Shen, Li, Kelley, Faber, Kim, Sungeun, Nho, Kwangsik, Kachaturian, Zaven, Frank, Richard, Snyder, Peter J, Molchan, Susan, Kaye, Jeffrey, Quinn, Joseph, Lind, Betty, Carter, Raina, Dolen, Sara, Schneider, Lon S, Pawluczyk, Sonia, Beccera, Mauricio, Teodoro, Liberty, Spann, Bryan M, Brewer, James, Van der Swag, Helen, Fleisher, Adam, Heidebrink, Judith L, Lord, Joanne L, Mason, Sara S, Albers, Colleen S, Knopman, David, Johnson, Kris, Doody, Rachelle S, Meyer, Javier Villanueva, Chowdhury, Munir, Rountree, Susan, Dang, Mimi, Stern, Yaakov, Honig, Lawrence S, Bell, Karen L, Ances, Beau, Morris, John C, Carroll, Maria, Leon, Sue, Mintun, Mark A, Schneider, Stacy, and Oliver, Angela
- Subjects
Clinical and Health Psychology ,Biomedical and Clinical Sciences ,Psychology ,Brain Disorders ,Mental Health ,Depression ,Mental Illness ,Mental health ,Alzheimer's Disease Neuroimaging Initiative ,apathy ,dementia ,depression ,latent class analysis ,Genetics ,Neurosciences ,Biological psychology - Abstract
Apathy is one of the most common neuropsychiatric symptoms (NPS) and is associated with poor clinical outcomes. Research that helps define the apathy phenotype is urgently needed, particularly for clinical and biomarker studies. We used latent class analysis (LCA) with two independent cohorts to understand how apathy and depression symptoms co-occur statistically. We further explored the relationship between latent class membership, demographics, and the presence of other NPS. The LCA identified a four-class solution (no symptoms, apathy, depression, and combined apathy/depression), reproducible over both cohorts, providing robust support for an apathy syndrome distinct from depression and confirming that an apathy/depression syndrome exists, supported by the model fit test with the four-class solution scores evidencing better fitting (Bayesian information criterion adjusted and entropy R 2). Using a data-driven method, we show distinct and statistically meaningful co-occurrence of apathy and depressive symptoms. There was evidence that these classes have different clinical associations, which may help inform diagnostic categories for research studies and clinical practice.HighlightsWe found four classes: no symptoms, apathy, depression and apathy/depression.Apathy conferred a higher probability for agitation.Apathy diagnostic criteria should include accompanying neuropsychiatric symptoms.
- Published
- 2023
7. Gait and balance in apolipoprotein Ɛ4 allele carriers in older adults and Parkinson’s disease
- Author
-
Morris, Rosie, Martini, Douglas N, Kelly, Valerie E, Smulders, Katrijn, Ramsey, Katrina, Hiller, Amie, Chung, Kathryn A, Hu, Shu-Ching, Zabetian, Cyrus P, Poston, Kathleen L, Mata, Ignacio F, Edwards, Karen L, Lapidus, Jodi, Cholerton, Brenna, Montine, Thomas J, Quinn, Joseph F, and Horak, Fay
- Subjects
Brain Disorders ,Clinical Research ,Parkinson's Disease ,Neurodegenerative ,Neurosciences ,Aging ,Acquired Cognitive Impairment ,2.1 Biological and endogenous factors ,Aetiology ,Neurological ,APOE ,Balance ,Gait ,Older adults ,Parkinson’s disease - Abstract
BackgroundGait and balance impairments are among the most troublesome and heterogeneous in Parkinson's disease (PD). This heterogeneity may, in part, reflect genetic variation. The apolipoprotein E (APOE) gene has three major allelic variants (ε2, ε3 and ε4). Previous work has demonstrated that older adult (OA) APOE ε4 carriers demonstrate gait deficits. This study compared gait and balance measures between APOE ε4 carriers and non-carriers in both OA and PD.Methods334 people with PD (81 APOE ε4 carriers and 253 non-carriers) and 144 OA (41 carriers and 103 non-carriers) were recruited. Gait and balance were assessed using body-worn inertial sensors. Two-way analyses of covariance (ANCOVA) compared gait and balance characteristics between APOE ε4 carriers and non-carriers in people with PD and OA, controlling for age, gender, and testing site.ResultsGait and balance were worse in people with PD compared to OA. However, there were no differences between APOE ε4 carriers and non-carriers in either the OA or PD group. In addition, there were no significant group (OA/PD) by APOE ε4 status (carrier/non-carrier) interaction effects for any measures of gait or balance.ConclusionsAlthough we found expected impairments in gait and balance in PD compared to OA, gait and balance characteristics did not differ between APOE ε4 carriers and non-carriers in either group. While APOE status did not impact gait and balance in this cross-sectional study, future work is needed to determine whether progression of gait and balance deficits is faster in PD APOE Ɛ4 carriers.
- Published
- 2023
8. α-Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α-Synuclein in the Context of Co-Pathology and Non-LBD Diagnoses.
- Author
-
Arnold, Moriah, Brumbach, Barbara, Smirnov, Denis, Concha-Marambio, Luis, Farris, Carly, Ma, Yihua, Kim, Yongya, Wilson, Edward, Kaye, Jeffrey, Hiniker, Annie, Woltjer, Randy, Galasko, Doug, Quinn, Joseph, and Coughlin, David
- Subjects
Brain ,Humans ,Sensitivity and Specificity ,alpha-Synuclein - Abstract
OBJECTIVE: The purpose of this study was to determine the sensitivity and specificity of α-synuclein seed amplification assay (αSyn-SAA) in antemortem and postmortem cerebrospinal fluid (CSF) of autopsy-confirmed patients with different distributions of pathological αSyn, co-pathologies, and clinical diagnoses. METHODS: The αSyn-SAA was used to test antemortem CSF samples from 119 subjects with a variety of clinical syndromes and standardized neuropathological examinations from Oregon Health and Science University (OHSU) and University of California San Diego (UCSD; 56 additional postmortem CSF samples available). The αSyn-SAA was also applied to frontal cortex and amygdala homogenates. Sensitivity and specificity were compared across distributions of αSyn pathology. Clinical data and co-pathologies were compared across αSyn-SAA positive and negative groups. RESULTS: Fifty-three individuals without and 66 with αSyn-pathology (neocortical [n = 38], limbic [n = 7], and amygdala-predominant [n = 21]) were included. There was a sensitivity of 97.8% and specificity of 98.1% of the αSyn-SAA to identify patients with limbic/neocortical pathology from antemortem CSF. Sensitivity to detect amygdala-predominant pathology was only 14.3%. Postmortem CSF and brain tissue αSyn-SAA analyses also showed higher assay positivity in samples from limbic/neocortical cases. INTERPRETATION: CSF αSyn-SAA reliably identifies αSyn seeds in patients with diffuse αSyn pathology in the context of co-pathology and non-Lewy body disease (LBD) diagnoses. The analysis of brain homogenates suggests that pathological αSyn in the amygdala might differ from pathological αSyn in the frontal cortex. The αSyn-SAA might facilitate the differential diagnosis of dementias with mixed pathologies. ANN NEUROL 2022;92:650-662.
- Published
- 2022
9. A Metabolomic Aging Clock Using Human Cerebrospinal Fluid.
- Author
-
Hwangbo, Nathan, Zhang, Xinyu, Raftery, Daniel, Gu, Haiwei, Hu, Shu-Ching, Montine, Thomas J, Quinn, Joseph F, Chung, Kathryn A, Hiller, Amie L, Wang, Dongfang, Fei, Qiang, Bettcher, Lisa, Zabetian, Cyrus P, Peskind, Elaine, Li, Gail, Promislow, Daniel EL, and Franks, Alexander
- Subjects
Medical Biochemistry and Metabolomics ,Biomedical and Clinical Sciences ,Aging ,Prevention ,Neurosciences ,Brain Disorders ,Acquired Cognitive Impairment ,Biotechnology ,Neurodegenerative ,Dementia ,Clinical Research ,Generic health relevance ,Biomarkers ,Cohort Studies ,Humans ,Mass Spectrometry ,Metabolome ,Metabolomics ,Aging clock ,Biomarker ,Cerebrospinal fluid ,Clinical Sciences ,Gerontology ,Biomedical and clinical sciences ,Health sciences - Abstract
Quantifying the physiology of aging is essential for improving our understanding of age-related disease and the heterogeneity of healthy aging. Recent studies have shown that, in regression models using "-omic" platforms to predict chronological age, residual variation in predicted age is correlated with health outcomes, and suggest that these "omic clocks" provide measures of biological age. This paper presents predictive models for age using metabolomic profiles of cerebrospinal fluid (CSF) from healthy human subjects and finds that metabolite and lipid data are generally able to predict chronological age within 10 years. We use these models to predict the age of a cohort of subjects with Alzheimer's and Parkinson's disease and find an increase in prediction error, potentially indicating that the relationship between the metabolome and chronological age differs with these diseases. However, evidence is not found to support the hypothesis that our models will consistently overpredict the age of these subjects. In our analysis of control subjects, we find the carnitine shuttle, sucrose, biopterin, vitamin E metabolism, tryptophan, and tyrosine to be the most associated with age. We showcase the potential usefulness of age prediction models in a small data set (n = 85) and discuss techniques for drift correction, missing data imputation, and regularized regression, which can be used to help mitigate the statistical challenges that commonly arise in this setting. To our knowledge, this work presents the first multivariate predictive metabolomic and lipidomic models for age using mass spectrometry analysis of CSF.
- Published
- 2022
10. Cognition as a mediator for gait and balance impairments in GBA-related Parkinson’s disease
- Author
-
Morris, Rosie, Martini, Douglas N, Ramsey, Katrina, Kelly, Valerie E, Smulders, Katrijn, Hiller, Amie, Chung, Kathryn A, Hu, Shu-Ching, Zabetian, Cyrus P, Poston, Kathleen L, Mata, Ignacio F, Edwards, Karen L, Lapidus, Jodi, Cholerton, Brenna, Montine, Thomas J, Quinn, Joseph F, and Horak, Fay
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Cognitive and Computational Psychology ,Neurosciences ,Psychology ,Aging ,Neurodegenerative ,Clinical Research ,Parkinson's Disease ,Brain Disorders ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Biological psychology ,Cognitive and computational psychology - Abstract
The extent to which the heterogeneity of gait and balance problems in PD may be explained by genetic variation is unknown. Variants in the glucocerebrosidase (GBA) gene are the strongest known genetic risk factor for PD and are associated with greater motor and cognitive severity. However, the impact of GBA variants on comprehensive measures of gait and balance and their relationship to cognition remains unknown. We aimed to determine differences in gait and balance impairments in those with and without GBA variants (mutation carriers and E326K polymorphism) and explore direct and indirect effects of GBA status on gait, balance, and cognition. 332 participants, 43 of whom had GBA variants, were recruited. Participants completed a comprehensive, objective assessment of gait and standing balance using body-worn inertial sensors. Group differences in gait and balance between PD with and without GBA variants were assessed with linear regression, adjusting for age, gender, clinical testing site, disease duration, and apolipoprotein E (APOE) ɛ4 status. Structural equation modeling (SEM) explored direct relationships between GBA status and gait and balance and indirect relationships between GBA status and gait and balance via cognition. The GBA variant group had more impaired gait (pace and variability) and balance (sway area/jerk and sway velocity), than the non-GBA variant group. SEM demonstrated cognition as a mediator of GBA status on gait and balance. The close relationships among GBA, gait/balance, and cognition suggest potential for novel therapeutics to target the GBA pathway and/or cognition to improve mobility in PD GBA variants.
- Published
- 2022
11. Predictive Modeling of Alzheimer’s and Parkinson’s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid
- Author
-
Hwangbo, Nathan, Zhang, Xinyu, Raftery, Daniel, Gu, Haiwei, Hu, Shu-Ching, Montine, Thomas J, Quinn, Joseph F, Chung, Kathryn A, Hiller, Amie L, Wang, Dongfang, Fei, Qiang, Bettcher, Lisa, Zabetian, Cyrus P, Peskind, Elaine R, Li, Ge, Promislow, Daniel EL, Davis, Marie Y, and Franks, Alexander
- Subjects
Medical Biochemistry and Metabolomics ,Analytical Chemistry ,Biomedical and Clinical Sciences ,Chemical Sciences ,Clinical Research ,Parkinson's Disease ,Alzheimer's Disease ,Neurodegenerative ,Dementia ,Aging ,Neurosciences ,Brain Disorders ,Acquired Cognitive Impairment ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Detection ,screening and diagnosis ,Aetiology ,2.1 Biological and endogenous factors ,4.1 Discovery and preclinical testing of markers and technologies ,Neurological ,predictive modeling ,biomarker ,cerebrospinal fluid ,cross-sectional study ,neurodegenerative disease ,Biochemistry and Cell Biology ,Clinical Sciences ,Biochemistry and cell biology ,Medical biochemistry and metabolomics ,Analytical chemistry - Abstract
In recent years, metabolomics has been used as a powerful tool to better understand the physiology of neurodegenerative diseases and identify potential biomarkers for progression. We used targeted and untargeted aqueous, and lipidomic profiles of the metabolome from human cerebrospinal fluid to build multivariate predictive models distinguishing patients with Alzheimer's disease (AD), Parkinson's disease (PD), and healthy age-matched controls. We emphasize several statistical challenges associated with metabolomic studies where the number of measured metabolites far exceeds sample size. We found strong separation in the metabolome between PD and controls, as well as between PD and AD, with weaker separation between AD and controls. Consistent with existing literature, we found alanine, kynurenine, tryptophan, and serine to be associated with PD classification against controls, while alanine, creatine, and long chain ceramides were associated with AD classification against controls. We conducted a univariate pathway analysis of untargeted and targeted metabolite profiles and find that vitamin E and urea cycle metabolism pathways are associated with PD, while the aspartate/asparagine and c21-steroid hormone biosynthesis pathways are associated with AD. We also found that the amount of metabolite missingness varied by phenotype, highlighting the importance of examining missing data in future metabolomic studies.
- Published
- 2022
12. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
- Author
-
Scott, Gregory D, Arnold, Moriah R, Beach, Thomas G, Gibbons, Christopher H, Kanthasamy, Anumantha G, Lebovitz, Russell M, Lemstra, Afina W, Shaw, Leslie M, Teunissen, Charlotte E, Zetterberg, Henrik, Taylor, Angela S, Graham, Todd C, Boeve, Bradley F, Gomperts, Stephen N, Graff-Radford, Neill R, Moussa, Charbel, Poston, Kathleen L, Rosenthal, Liana S, Sabbagh, Marwan N, Walsh, Ryan R, Weber, Miriam T, Armstrong, Melissa J, Bang, Jee A, Bozoki, Andrea C, Domoto-Reilly, Kimiko, Duda, John E, Fleisher, Jori E, Galasko, Douglas R, Galvin, James E, Goldman, Jennifer G, Holden, Samantha K, Honig, Lawrence S, Huddleston, Daniel E, Leverenz, James B, Litvan, Irene, Manning, Carol A, Marder, Karen S, Pantelyat, Alexander Y, Pelak, Victoria S, Scharre, Douglas W, Sha, Sharon J, Shill, Holly A, Mari, Zoltan, Quinn, Joseph F, and Irwin, David J
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Clinical Sciences ,Neurosciences ,Psychology ,Alzheimer's Disease Related Dementias (ADRD) ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Alzheimer's Disease ,Aging ,Dementia ,Brain Disorders ,Acquired Cognitive Impairment ,Lewy Body Dementia ,Parkinson's Disease ,Neurodegenerative ,Neurological ,cerebrospinal fluid ,alpha-synuclein ,skin biopsy ,seeded aggregation assays ,tau ,amyloid ,Lewy body dementia ,LBDA biomarker symposium ,Clinical sciences ,Biological psychology - Abstract
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and Parkinson's disease dementia (PDD). The meeting featured eight internationally known scientists from Europe and the United States and attracted over 200 scientists and physicians from academic centers, the National Institutes of Health, and the pharmaceutical industry. Methods for confirming and quantifying the presence of Lewy body and Alzheimer's pathology and novel biomarkers were discussed.
- Published
- 2022
13. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- Author
-
McGarry, Andrew, Rosanbalm, Shane, Leinonen, Mika, Olanow, C Warren, To, Dennis, Bell, Adam, Lee, Daniel, Chang, Jamie, Dubow, Jordan, Dhall, Rohit, Burdick, Daniel, Parashos, Sotirios, Feuerstein, Jeanne, Quinn, Joseph, Pahwa, Rajesh, Afshari, Mitra, Ramirez-Zamora, Aldolfo, Chou, Kelvin, Tarakad, Arjun, Luca, Corneliu, Klos, Kevin, Bordelon, Yvette, St Hiliare, Marie-Helene, Shprecher, David, Lee, Seulki, Dawson, Ted M, Roschke, Viktor, and Kieburtz, Karl
- Published
- 2024
- Full Text
- View/download PDF
14. Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson’s disease
- Author
-
Cholerton, Brenna A, Poston, Kathleen L, Yang, Laurice, Rosenthal, Liana S, Dawson, Ted M, Pantelyat, Alexander, Edwards, Karen L, Tian, Lu, Quinn, Joseph F, Chung, Kathryn A, Hiller, Amie L, Hu, Shu-Ching, Montine, Thomas J, and Zabetian, Cyrus P
- Subjects
Biological Psychology ,Psychology ,Acquired Cognitive Impairment ,Neurosciences ,Behavioral and Social Science ,Clinical Research ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Dementia ,Neurodegenerative ,Clinical Trials and Supportive Activities ,Parkinson's Disease ,Brain Disorders ,Aging ,Neurological ,Cognition ,Cognitive Dysfunction ,Humans ,Neuropsychological Tests ,Parkinson Disease ,Semantics ,cognition ,healthy volunteers ,neuropsychological assessment ,Parkinson's disease ,Parkinson’s disease ,Cognitive Sciences ,Experimental Psychology ,Biological psychology ,Clinical and health psychology ,Cognitive and computational psychology - Abstract
Introduction: Parkinson's disease (PD) is associated with a range of cognitive deficits. Few studies have carefully examined the subtle impacts of PD on cognition among patients who do not meet formal criteria for MCI or dementia. The aim of the current study was thus to describe the impact of PD on cognition in those without cognitive impairment in a well-characterized cohort.Methods: Non-cognitively impaired participants (122 with PD, 122 age- and sex-matched healthy volunteers) underwent extensive cognitive testing. Linear regression analyses compared diagnostic group performance across cognitive measures. For cognitive tasks that were significantly different between groups, additional analyses examined group differences restricting the group inclusion to PD participants with mild motor symptoms or disease duration less than 10 years.Results: Processing speed and semantic verbal fluency were significantly lower in the PD group (B = -3.77, 95% CIs [-5.76 to -1.77], p
- Published
- 2021
15. Feedback Motion Planning for Long-Range Autonomous Underwater Vehicles
- Author
-
Orioke, Opeyemi S., Alam, Tauhidul, Quinn, Joseph, Kaur, Ramneek, Alsabban, Wesam H., Bobadilla, Leonardo, and Smith, Ryan N.
- Subjects
Computer Science - Robotics - Abstract
Ocean ecosystems have spatiotemporal variability and dynamic complexity that require a long-term deployment of an autonomous underwater vehicle for data collection. A new long-range autonomous underwater vehicle called Tethys is adapted to study different oceanic phenomena. Additionally, an ocean environment has external forces and moments along with changing water currents which are generally not considered in a vehicle kinematic model. In this scenario, it is not enough to generate a simple trajectory from an initial location to a goal location in an uncertain ocean as the vehicle can deviate from its intended trajectory. As such, we propose to compute a feedback plan that adapts the vehicle trajectory in the presence of any modeled or unmodeled uncertainties. In this work, we present a feedback motion planning method for the Tethys vehicle by combining a predictive ocean model and its kinematic modeling. Given a goal location, the Tethys kinematic model, and the water flow pattern, our method computes a feedback plan for the vehicle in a dynamic ocean environment that reduces its energy consumption. The computed feedback plan provides the optimal action for the Tethys vehicle to take from any location of the environment to reach the goal location considering its orientation. Our results based on actual ocean model prediction data demonstrate the applicability of our method., Comment: IEEE/MTS OCEANS-Marseille 2019
- Published
- 2019
16. Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data
- Author
-
Kaddurah-Daouk, Rima, Kueider-Paisley, Alexandra, Doraiswamy, P. Murali, Blach, Colette, Moseley, Arthur, Thompson, Will, St John-Williams, Lisa, Mahmoudiandehkhordi, Siamak, Tenenbaum, Jessica, Welsh-Balmer, Kathleen, Plassman, Brenda, Saykin, Andrew J., Nho, Kwangsik, Risacher, Shannon L., Kastenmüller, Gabi, Arnold, Matthias, Han, Xianlin, Baillie, Rebecca, Knight, Rob, Dorrestein, Pieter, Brewer, James, Mayer, Emeran, Labus, Jennifer, Baldi, Pierre, Gupta, Arpana, Fiehn, Oliver, Barupal, Dinesh, Meikle, Peter, Mazmanian, Sarkis, Rader, Dan, Kling, Mitchel, Shaw, Leslie, Trojanowski, John, van Duijin, Cornelia, Nevado-Holgado, Alejo, Bennett, David, Krishnan, Ranga, Keshavarzian, Ali, Vogt, Robin, Ikram, Arfan, Hankemeier, Thomas, Thiele, Ines, Price, Nathan, Funk, Cory, Baloni, Priyanka, Jia, Wei, Wishart, David, Brinton, Roberta, Chang, Rui, Farrer, Lindsay, Au, Rhoda, Qiu, Wendy, Würtz, Peter, Koal, Therese, Mangravite, Lara, Krumsiek, Jan, Suhre, Karsten, Newman, John, Moreno, Herman, Foroud, Tatania, Sacks, Frank, Jansson, Janet, Weiner, Michael W., Aisen, Paul, Petersen, Ronald, Jack, Clifford R., Jr., Jagust, William, Trojanowki, John Q., Toga, Arthur W., Beckett, Laurel, Green, Robert C., Morris, John C., Perrin, Richard J., Shaw, Leslie M., Khachaturian, Zaven, Carrillo, Maria, Potter, William, Barnes, Lisa, Bernard, Marie, Gonzalez, Hector, Ho, Carole, Hsiao, John K., Jackson, Jonathan, Masliah, Eliezer, Masterman, Donna, Okonkwo, Ozioma, Perrin, Richard, Ryan, Laurie, Silverberg, Nina, Fleisher, Adam, Sacrey, Diana Truran, Fockler, Juliet, Conti, Cat, Veitch, Dallas, Neuhaus, John, Jin, Chengshi, Nosheny, Rachel, Ashford, Miriam, Flenniken, Derek, Kormos, Adrienne, Montine, Tom, Rafii, Michael, Raman, Rema, Jimenez, Gustavo, Donohue, Michael, Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah, Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Smith, Stephanie, Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth, Sloan, Brittany, Harvey, Danielle, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Schwarz, Christopher, Jones, David, Gunter, Jeff, Kantarci, Kejal, Senjem, Matthew, Vemuri, Prashanthi, Reid, Robert, Fox, Nick C., Malone, Ian, Thompson, Paul, Thomopoulos, Sophia I., Nir, Talia M., Jahanshad, Neda, DeCarli, Charles, Knaack, Alexander, Fletcher, Evan, Tosun-Turgut, Duygu, Chen, Stephanie Rossi, Choe, Mark, Crawford, Karen, Yushkevich, Paul A., Das, Sandhitsu, Koeppe, Robert A., Reiman, Eric M., Chen, Kewei, Mathis, Chet, Landau, Susan, Cairns, Nigel J., Householder, Erin, Franklin, Erin, Bernhardt, Haley, Taylor-Reinwald, Lisa, Korecka, Magdalena, Figurski, Michal, Neu, Scott, Apostolova, Liana G., Shen, Li, Foroud, Tatiana M., Nudelman, Kelly, Faber, Kelley, Wilmes, Kristi, Thal, Leon, Silbert, Lisa C., Lind, Betty, Crissey, Rachel, Kaye, Jeffrey A., Carter, Raina, Dolen, Sara, Quinn, Joseph, Schneider, Lon S., Pawluczyk, Sonia, Becerra, Mauricio, Teodoro, Liberty, Dagerman, Karen, Spann, Bryan M., Vanderswag, Helen, Ziolkowski, Jaimie, Heidebrink, Judith L., Zbizek-Nulph, Lisa, Lord, Joanne L., Mason, Sara S., Albers, Colleen S., Knopman, David, Johnson, Kris, Villanueva-Meyer, Javier, Pavlik, Valory, Pacini, Nathaniel, Lamb, Ashley, Kass, Joseph S., Doody, Rachelle S., Shibley, Victoria, Chowdhury, Munir, Rountree, Susan, Dang, Mimi, Stern, Yaakov, Honig, Lawrence S., Mintz, Akiva, Ances, Beau, Winkfield, David, Carroll, Maria, Stobbs-Cucchi, Georgia, Oliver, Angela, Creech, Mary L., Mintun, Mark A., Schneider, Stacy, Geldmacher, David, Love, Marissa Natelson, Griffith, Randall, Clark, David, Brockington, John, Marson, Daniel, Grossman, Hillel, Goldstein, Martin A., Greenberg, Jonathan, Mitsis, Effie, Shah, Raj C., Lamar, Melissa, Samuels, Patricia, Duara, Ranjan, Greig-Custo, Maria T., Rodriguez, Rosemarie, Albert, Marilyn, Onyike, Chiadi, Farrington, Leonie, Rudow, Scott, Brichko, Rottislav, Kielb, Stephanie, Smith, Amanda, Raj, Balebail Ashok, Fargher, Kristin, Sadowski, Martin, Wisniewski, Thomas, Shulman, Melanie, Faustin, Arline, Rao, Julia, Castro, Karen M., Ulysse, Anaztasia, Chen, Shannon, Sheikh, Mohammed O., Singleton-Garvin, Jamika, Petrella, JeffreyR., James, Olga, Wong, Terence Z., Borges-Neto, Salvador, Karlawish, Jason H., Wolk, David A., Vaishnavi, Sanjeev, Clark, Christopher M., Arnold, Steven E., Smith, Charles D., Jicha, Gregory A., Raslau, Flavius D., Lopez, Oscar L., Oakley, MaryAnn, Simpson, Donna M., Porsteinsson, Anton P., Martin, Kim, Kowalski, Nancy, Keltz, Melanie, Goldstein, Bonnie S., Makino, Kelly M., Ismail, M. Saleem, Brand, Connie, Thai, Gaby, Pierce, Aimee, Yanez, Beatriz, Sosa, Elizabeth, Witbracht, Megan, Kelley, Brendan, Nguyen, Trung, Womack, Kyle, Mathews, Dana, Quiceno, Mary, Levey, Allan I., Lah, James J., Hajjar, Ihab, Cellar, Janet S., Burns, Jeffrey M., Swerdlow, Russell H., Brooks, William M., Silverman, Daniel H.S., Kremen, Sarah, Apostolova, Liana, Tingus, Kathleen, Lu, Po H., Bartzokis, George, Woo, Ellen, Teng, Edmond, Graff-Radford, Neill R., Parfitt, Francine, Poki-Walker, Kim, Farlow, Martin R., Hake, Ann Marie, Matthews, Brandy R., Brosch, Jared R., Herring, Scott, van, Christopher H., Mecca, Adam P., Good, Susan P., MacAvoy, Martha G., Carson, Richard E., Varma, Pradeep, Chertkow, Howard, Vaitekunis, Susan, Hosein, Chris, Black, Sandra, Stefanovic, Bojana, Heyn, Chris (Chinthaka), Robin Hsiung, Ging-Yuek, Kim, Ellen, Mudge, Benita, Sossi, Vesna, Feldman, Howard, Assaly, Michele, Finger, Elizabeth, Pasternak, Stephen, Rachinsky, Irina, Kertesz, Andrew, Drost, Dick, Rogers, John, Grant, Ian, Muse, Brittanie, Rogalski, Emily, Robson, Jordan, Mesulam, M.-Marsel, Kerwin, Diana, Wu, Chuang-Kuo, Johnson, Nancy, Lipowski, Kristine, Weintraub, Sandra, Bonakdarpour, Borna, Pomara, Nunzio, Hernando, Raymundo, Sarrael, Antero, Rosen, Howard J., Miller, Bruce L., Perry, David, Turner, Raymond Scott, Johnson, Kathleen, Reynolds, Brigid, MCCann, Kelly, Poe, Jessica, Sperling, Reisa A., Johnson, Keith A., Marshall, Gad A., Yesavage, Jerome, Taylor, Joy L., Chao, Steven, Coleman, Jaila, White, Jessica D., Lane, Barton, Rosen, Allyson, Tinklenberg, Jared, Belden, Christine M., Atri, Alireza, Clark, Kelly A., Zamrini, Edward, Sabbagh, Marwan, Killiany, Ronald, Stern, Robert, Mez, Jesse, Kowall, Neil, Budson, Andrew E., Obisesan, Thomas O., Ntekim, Oyonumo E., Wolday, Saba, Khan, Javed I., Nwulia, Evaristus, Nadarajah, Sheeba, Lerner, Alan, Ogrocki, Paula, Tatsuoka, Curtis, Fatica, Parianne, Maillard, Pauline, Olichney, John, Carmichael, Owen, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Borrie, Michael, Lee, T.-Y., Bartha, Dr Rob, Johnson, Sterling, Asthana, Sanjay, Carlsson, Cynthia M., Perrin, Allison, Burke, Anna, Scharre, Douglas W., Kataki, Maria, Tarawneh, Rawan, Hart, David, Zimmerman, Earl A., Celmins, Dzintra, Miller, Delwyn D., BolesPonto, Laura L., Smith, Karen Ekstam, Koleva, Hristina, Shim, Hyungsub, Nam, Ki Won, Schultz, Susan K., Williamson, Jeff D., Craft, Suzanne, Cleveland, Jo, Yang, Mia, Sink, Kaycee M., Ott, Brian R., Drake, Jonathan, Tremont, Geoffrey, Daiello, Lori A., Drake, Jonathan D., Ritter, Aaron, Bernick, Charles, Munic, Donna, O'Connelll, Abigail, Mintzer, Jacobo, Wiliams, Arthur, Masdeu, Joseph, Shi, Jiong, Garcia, Angelica, Newhouse, Paul, Potkin, Steven, Salloway, Stephen, Malloy, Paul, Correia, Stephen, Kittur, Smita, Pearlson, Godfrey D., Blank, Karen, Anderson, Karen, Flashman, Laura A., Seltzer, Marc, Hynes, Mary L., Santulli, Robert B., Relkin, Norman, Chiang, Gloria, Lee, Athena, Lin, Michael, Ravdin, Lisa, Petersen, Ron, Neylan, Thomas, Grafman, Jordan, Danowski, Sarah, Nguyen-Barrera, Catherine, Hayes, Jacqueline, Finley, Shannon, Bernstein, Matthew, Senjem, Matt, Foster, Norm, Kim, Sungeun, Sood, Ajay, Blanchard, Kimberly S., Fleischman, Debra, Arfanakis, Konstantinos, Varon, Daniel, Greig, Maria T., Petrella, Jeffrey R., Goldstein, Bonnie, Martin, Kimberly S., Reist, Christopher, Sadowsky, Carl, Martinez, Walter, Villena, Teresa, Rosen, Howard, Marshall, Gad, Peskind, Elaine R., Petrie, Eric C., Li, Gail, Mackin, Scott, Jimenez-Maggiora, Gustavo, Drake, Erin, Donohue, Mike, Nelson, Craig, Bickford, David, Butters, Meryl, Zmuda, Michelle, Reyes, Denise, Faber, Kelley M., Nudelman, Kelly N., Au, Yiu Ho, Scherer, Kelly, Catalinotto, Daniel, Stark, Samuel, Ong, Elise, Fernandez, Dariella, Jo, Taeho, Kim, Junpyo, Bice, Paula, Huynh, Kevin, Wang, Tingting, Meikle, Peter J., and Giles, Corey
- Published
- 2023
- Full Text
- View/download PDF
17. Relationships Between Sensorimotor Inhibition and Mobility in Older Adults With and Without Parkinson's Disease.
- Author
-
Martini, Douglas N, Morris, Rosie, Madhyastha, Tara M, Grabowski, Thomas J, Oakley, John, Hu, Shu-Ching, Zabetian, Cyrus P, Edwards, Karen L, Hiller, Amie, Chung, Kathryn, Ramsey, Katrina, Lapidus, Jodi A, Cholerton, Brenna, Montine, Thomas J, Quinn, Joseph F, and Horak, Fay B
- Subjects
Brain Disorders ,Clinical Research ,Neurodegenerative ,Parkinson's Disease ,Neurosciences ,Aging ,Neurological ,Accidental Falls ,Aged ,Cognition ,Cognitive Dysfunction ,Correlation of Data ,Evoked Potentials ,Motor ,Executive Function ,Female ,Gait Disorders ,Neurologic ,Humans ,Male ,Mental Status and Dementia Tests ,Neural Inhibition ,Parkinson Disease ,Postural Balance ,Sensory Gating ,Transcranial Magnetic Stimulation ,Walking ,Gait ,Short-latency afferent inhibition ,Transcranial magnetic stimulation ,Clinical Sciences ,Gerontology - Abstract
BackgroundReduced cortical sensorimotor inhibition is associated with mobility and cognitive impairments in people with Parkinson's disease (PD) and older adults (OAs). However, there is a lack of clarity regarding the relationships among sensorimotor, cognitive, and mobility impairments. The purpose of this study was to determine how cortical sensorimotor inhibition relates to impairments in mobility and cognition in people with PD and OAs.MethodCortical sensorimotor inhibition was characterized with short-latency afferent inhibition (SAI) in 81 people with PD and 69 OAs. Six inertial sensors recorded single- and dual-task gait and postural sway characteristics during a 2-minute walk and a 1-minute quiet stance. Cognition was assessed across the memory, visuospatial, executive function, attention, and language domains.ResultsSAI was significantly impaired in the PD compared to the OA group. The PD group preformed significantly worse across all gait and postural sway tasks. In PD, SAI significantly correlated with single-task foot strike angle and stride length variability, sway area, and jerkiness of sway in the coronal and sagittal planes. In OAs, SAI significantly related to single-task gait speed and stride length, dual-task stride length, and immediate recall (memory domain). No relationship among mobility, cognition, and SAI was observed.ConclusionsImpaired SAI related to slower gait in OA and to increased gait variability and postural sway in people with PD, all of which have been shown to be related to increased fall risk.
- Published
- 2021
18. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
- Author
-
Höglinger, Günter U, Litvan, Irene, Mendonca, Nuno, Wang, Deli, Zheng, Hui, Rendenbach-Mueller, Beatrice, Lon, Hoi-Kei, Jin, Ziyi, Fisseha, Nahome, Budur, Kumar, Gold, Michael, Ryman, Davis, Florian, Hana, Investigators, Arise, Ahmed, Anwar, Aiba, Ikuko, Albanese, Alberto, Bertram, Kelly, Bordelon, Yvette, Bower, James, Brosch, Jared, Claassen, Daniel, Colosimo, Carlo, Corvol, Jean-Christophe, Cudia, Paola, Daniele, Antonio, Defebvre, Luc, Driver-Dunckley, Erika, Duquette, Antoine, Eleopra, Roberto, Eusebio, Alexandre, Fung, Victor, Geldmacher, David, Golbe, Lawrence, Grandas, Francisco, Hall, Deborah, Hatano, Taku, Honig, Lawrence, Hui, Jennifer, Kerwin, Diana, Kikuchi, Akio, Kimber, Thomas, Kimura, Takashi, Kumar, Rajeev, Ljubenkov, Peter, Lorenzl, Stefan, Ludolph, Albert, Mari, Zoltan, McFarland, Nikolaus, Meissner, Wassilios, Rivera, Pablo Mir, Mochizuki, Hidek, Morgan, John, Munhoz, Renato, Nishikawa, Noriko, O`Sullivan, John, Oeda, Tomoko, Oizumi, Hideki, Onodera, Osamu, Ory-Magne, Fabienne, Peckham, Elizabeth, Postuma, Ronald, Quattrone, Aldo, Quinn, Joseph, Ruggieri, Stefano, Sarna, Justyna, Schulz, Paul E, Slevin, John, Tagliati, Michele, Wile, Daryl, Wszolek, Zbigniew, Xie, Tao, and Zesiewicz, Theresa
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Brain Disorders ,Clinical Research ,Clinical Trials and Supportive Activities ,Patient Safety ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Neurological ,Administration ,Intravenous ,Aged ,Antibodies ,Monoclonal ,Humanized ,Double-Blind Method ,Female ,Humans ,Male ,Middle Aged ,Supranuclear Palsy ,Progressive ,Treatment Outcome ,tau Proteins ,Arise Investigators ,Neurology & Neurosurgery ,Clinical sciences - Abstract
BackgroundProgressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.MethodsWe did a phase 2, multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Australia, Canada, France, Germany, Italy, Japan, Spain, and the USA. Participants (aged ≥40 years) diagnosed with possible or probable progressive supranuclear palsy who were symptomatic for less than 5 years, had a reliable study partner, and were able to walk five steps with minimal assistance, were randomly assigned (1:1:1) by interactive response technology to tilavonemab 2000 mg, tilavonemab 4000 mg, or matching placebo administered intravenously on days 1, 15, and 29, then every 28 days through to the end of the 52-week treatment period. Randomisation was done by the randomisation specialist of the study sponsor, who did not otherwise participate in the study. The sponsor, investigators, and participants were unaware of treatment allocations. The primary endpoint was the change from baseline to week 52 in the Progressive Supranuclear Palsy Rating Scale (PSPRS) total score in the intention-to-treat population. Adverse events were monitored in participants who received at least one dose of study drug. Prespecified interim futility criteria were based on a model-based effect size of 0 or lower when 60 participants had completed the 52-week treatment period and 0·12 or lower when 120 participants had completed the 52-week treatment period. This study is registered at ClinicalTrials.gov, number NCT02985879.FindingsBetween Dec 12, 2016, and Dec 31, 2018, 466 participants were screened, 378 were randomised. The study was terminated on July 3, 2019, after prespecified futility criteria were met at the second interim analysis. A total of 377 participants received at least one dose of study drug and were included in the efficacy and safety analyses (2000 mg, n=126; 4000 mg, n=125; placebo, n=126). Least squares mean change from baseline to week 52 in PSPRS was similar in all groups (between-group difference vs placebo: 2000 mg, 0·0 [95% CI -2·6 to 2·6], effect size 0·000, p>0·99; 4000 mg, 1·0 [-1·6 to 3·6], -0·105, p=0·46). Most participants reported at least one adverse event (2000 mg, 111 [88%]; 4000 mg, 111 [89%]; placebo, 108 [86%]). Fall was the most common adverse event (2000 mg, 42 [33%]; 4000 mg, 54 [43%]; placebo, 49 [39%]). Proportions of patients with serious adverse events were similar among groups (2000 mg, 29 [23%]; 4000 mg, 34 [27%]; placebo, 33 [26%]). Fall was the most common treatment-emergent serious adverse event (2000 mg, five [4%]; 4000 mg, six [5%]; placebo, six [5%]). 26 deaths occurred during the study (2000 mg, nine [7%]; 4000 mg, nine [7%]; placebo, eight [6%]) but none was drug related.InterpretationA similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy.FundingAbbVie Inc.
- Published
- 2021
19. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntingtons Disease Patients-A Randomized Phase 2 Clinical Trial.
- Author
-
Brownstein, Michael, Simon, Neal, Long, Jeffrey, Yankey, Jon, Maibach, Hilda, Cudkowicz, Merit, Coffey, Christopher, Conwit, Robin, Lungu, Codrin, Anderson, Karen, Hersch, Steven, Ecklund, Dixie, Damiano, Eve, Itzkowitz, Debra, Lu, Shifang, Chase, Marianne, Shefner, Jeremy, McGarry, Andrew, Thornell, Brenda, Gladden, Catherine, Costigan, Michele, OSuilleabhain, Padraig, Marshall, Frederick, Chesire, Amy, Deritis, Paul, Adams, Jamie, Hedera, Peter, Lowen, Kelly, Rosas, H, Hiller, Amie, Quinn, Joseph, Keith, Kellie, Duker, Andrew, Gruenwald, Christina, Molloy, Angela, Jacob, Cara, Factor, Stewart, Sperin, Elaine, Bega, Danny, Brown, Zsazsa, Seeberger, Lauren, Sung, Victor, Benge, Melanie, Kostyk, Sandra, Daley, Allison, Perlman, Susan, Suski, Valerie, Conlon, Patricia, Barrett, Matthew, Lowenhaupt, Stephanie, Quigg, Mark, Perlmutter, Joel, Wright, Brenton, Most, Elaine, Schwartz, Guy, Lamb, Jessica, Chuang, Rosalind, Singer, Carlos, Marder, Karen, Moran, Joyce, Singleton, John, Zorn, Meghan, Wall, Paola, Dubinsky, Richard, Gray, Carolyn, and Drazinic, Carolyn
- Subjects
Huntington’s disease ,safety ,tolerability ,vasopressin 1a receptor antagonist - Abstract
SRX246 is a vasopressin (AVP) 1a receptor antagonist that crosses the blood-brain barrier. It reduced impulsive aggression, fear, depression and anxiety in animal models, blocked the actions of intranasal AVP on aggression/fear circuits in an experimental medicine fMRI study and demonstrated excellent safety in Phase 1 multiple-ascending dose clinical trials. The present study was a 3-arm, multicenter, randomized, placebo-controlled, double-blind, 12-week, dose escalation study of SRX246 in early symptomatic Huntingtons disease (HD) patients with irritability. Our goal was to determine whether SRX246 was safe and well tolerated in these HD patients given its potential use for the treatment of problematic neuropsychiatric symptoms. Participants were randomized to receive placebo or to escalate to 120 mg twice daily or 160 mg twice daily doses of SRX246. Assessments included standard safety tests, the Unified Huntingtons Disease Rating Scale (UHDRS), and exploratory measures of problem behaviors. The groups had comparable demographics, features of HD and baseline irritability. Eighty-two out of 106 subjects randomized completed the trial on their assigned dose of drug. One-sided exact-method confidence interval tests were used to reject the null hypothesis of inferior tolerability or safety for each dose group vs. placebo. Apathy and suicidality were not affected by SRX246. Most adverse events in the active arms were considered unlikely to be related to SRX246. The compound was safe and well tolerated in HD patients and can be moved forward as a candidate to treat irritability and aggression.
- Published
- 2020
20. Multivariate prediction of dementia in Parkinson’s disease
- Author
-
Phongpreecha, Thanaphong, Cholerton, Brenna, Mata, Ignacio F, Zabetian, Cyrus P, Poston, Kathleen L, Aghaeepour, Nima, Tian, Lu, Quinn, Joseph F, Chung, Kathryn A, Hiller, Amie L, Hu, Shu-Ching, Edwards, Karen L, and Montine, Thomas J
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Cognitive and Computational Psychology ,Neurosciences ,Psychology ,Neurodegenerative ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Acquired Cognitive Impairment ,Prevention ,Brain Disorders ,Alzheimer's Disease ,Alzheimer's Disease Related Dementias (ADRD) ,Dementia ,Aging ,Clinical Research ,Behavioral and Social Science ,Parkinson's Disease ,2.1 Biological and endogenous factors ,2.3 Psychological ,social and economic factors ,Aetiology ,Neurological ,Parkinson's disease ,Biological psychology ,Cognitive and computational psychology - Abstract
Cognitive impairment in Parkinson's disease (PD) is pervasive with potentially devastating effects. Identification of those at risk for cognitive decline is vital to identify and implement appropriate interventions. Robust multivariate approaches, including fixed-effect, mixed-effect, and multitask learning models, were used to study associations between biological, clinical, and cognitive factors and for predicting cognitive status longitudinally in a well-characterized prevalent PD cohort (n = 827). Age, disease duration, sex, and GBA status were the primary biological factors associated with cognitive status and progression to dementia. Specific cognitive tests were better predictors of subsequent cognitive status for cognitively unimpaired and dementia groups. However, these models could not accurately predict future mild cognitive impairment (PD-MCI). Data collected from a large PD cohort thus revealed the primary biological and cognitive factors associated with dementia, and provide clinicians with data to aid in the identification of risk for dementia. Sex differences and their potential relationship to genetic status are also discussed.
- Published
- 2020
21. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.
- Author
-
Cudkowicz, Merit, Chase, Marianne, Coffey, Christopher, Ecklund, Dixie, Thornell, Brenda, Lungu, Codrin, Mahoney, Katy, Gutmann, Laurie, Shefner, Jeremy, Staley, Kevin, Bosch, Michael, Foster, Eric, Long, Jeffrey, Bayman, Emine, Torner, James, Yankey, Jon, Peters, Richard, Huff, Trevis, Conwit, Robin, Shinnar, Shlomo, Patch, Donna, Darras, Basil, Ellis, Audrey, Packer, Roger, Marder, Karen, Chiriboga, Claudia, Moran, Joyce, Nikolov, Blagovest, Factor, Stewart, Seeley, Carole, Greenberg, Steven, Amato, Anthony, DeGregorio, Sara, Simuni, Tanya, Ward, Tina, Kissel, John, Kolb, Stephen, Bartlett, Amy, Quinn, Joseph, Keith, Kellie, Levine, Steven, Gilles, Nadege, Coyle, Patricia, Lamb, Jessica, Wolfe, Gil, Crumlish, Annemarie, Mejico, Luis, Iqbal, Muhammad, Bowen, James, Tongco, Caryl, Nabors, Louis, Bashir, Khurram, Benge, Melanie, Canamar, Catherine, Glauser, Tracy, Woo, Daniel, Molloy, Angela, Clark, Peggy, Vollmer, Timothy, Stein, Alexander, Barohn, Richard, Dimachkie, Mazen, Le Pichon, Jean-Baptiste, Benatar, Michael, Steele, Julie, Wechsler, Lawrence, Clemens, Paula, Amity, Christine, Holloway, Robert, Annis, Christine, Goldberg, Mark, Andersen, Mariam, Iannaccone, Susan, Smith, A, Singleton, J, Doudova, Mariana, Haley, E, Quigg, Mark, Lowenhaupt, Stephanie, Malow, Beth, Adkins, Karen, Clifford, David, Teshome, Mengesha, Connolly, Noreen, Oskarsson, Björn, Dobkin, Bruce, McDonald, Craig, Henricson, Erik, and Henchcliffe, Claire
- Subjects
Clinical Trials as Topic ,Humans ,National Institute of Neurological Disorders and Stroke (U.S.) ,Nervous System Diseases ,Neurology ,Neurosciences ,United States - Abstract
IMPORTANCE: One major advantage of developing large, federally funded networks for clinical research in neurology is the ability to have a trial-ready network that can efficiently conduct scientifically rigorous projects to improve the health of people with neurologic disorders. OBSERVATIONS: National Institute of Neurological Disorders and Stroke Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) was established in 2011 and renewed in 2018 with the goal of being an efficient network to test between 5 and 7 promising new agents in phase II clinical trials. A clinical coordinating center, data coordinating center, and 25 sites were competitively chosen. Common infrastructure was developed to accelerate timelines for clinical trials, including central institutional review board (a first for the National Institute of Neurological Disorders and Stroke), master clinical trial agreements, the use of common data elements, and experienced research sites and coordination centers. During the first 7 years, the network exceeded the goal of conducting 5 to 7 studies, with 9 funded. High interest was evident by receipt of 148 initial applications for potential studies in various neurologic disorders. Across the first 8 studies (the ninth study was funded at end of initial funding period), the central institutional review board approved the initial protocol in a mean (SD) of 59 (21) days, and additional sites were added a mean (SD) of 22 (18) days after submission. The median time from central institutional review board approval to first site activation was 47.5 days (mean, 102.1; range, 1-282) and from first site activation to first participant consent was 27 days (mean, 37.5; range, 0-96). The median time for database readiness was 3.5 months (mean, 4.0; range, 0-8) from funding receipt. In the 4 completed studies, enrollment met or exceeded expectations with 96% overall data accuracy across all sites. Nine peer-reviewed manuscripts were published, and 22 oral presentations or posters and 9 invited presentations were given at regional, national, and international meetings. CONCLUSIONS AND RELEVANCE: NeuroNEXT initiated 8 studies, successfully enrolled participants at or ahead of schedule, collected high-quality data, published primary results in high-impact journals, and provided mentorship, expert statistical, and trial management support to several new investigators. Partnerships were successfully created between government, academia, industry, foundations, and patient advocacy groups. Clinical trial consortia can efficiently and successfully address a range of important neurologic research and therapeutic questions.
- Published
- 2020
22. Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy
- Author
-
VandeVrede, Lawren, Dale, Marian L, Fields, Scott, Frank, Megan, Hare, Emma, Heuer, Hilary W, Keith, Kellie, Koestler, Mary, Ljubenkov, Peter A, McDermott, Dana, Ohanesian, Noelle, Richards, Jennifer, Rojas, Julio C, Thijssen, Elisabeth H, Walsh, Christine, Wang, Ping, Wolf, Amy, Quinn, Joseph F, Tsai, Richard, and Boxer, Adam L
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Clinical Research ,Rare Diseases ,Orphan Drug ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Neurological ,progressive supranuclear palsy ,salsalate ,young plasma ,4RTNI ,PSPRS ,Clinical sciences - Abstract
BackgroundProgressive supranuclear palsy (PSP) is a neurodegenerative disease without approved therapies, and therapeutics are often tried off-label in the hope of slowing disease progression. Results from these experiences are seldom shared, which limits evidence-based knowledge to guide future treatment decisions.ObjectivesTo describe an open-label experience, including safety/tolerability, and longitudinal changes in biomarkers of disease progression in PSP-Richardson's syndrome (PSP-RS) patients treated with either salsalate or young plasma and compare to natural history data from previous multicenter studies.MethodsFor 6 months, 10 PSP-RS patients received daily salsalate 2,250 mg, and 5 patients received monthly infusions of four units of young plasma. Every 3 months, clinical severity was assessed with the Progressive Supranuclear Palsy Rating Scale (PSPRS), and MRI was obtained for volumetric measurement of midbrain. A range of exploratory biomarkers, including cerebrospinal fluid levels of neurofilament light chain, were collected at baseline and 6 months. Interventional data were compared to historical PSP-RS patients from the davunetide clinical trial and the 4-Repeat Tauopathy Neuroimaging Initiative.ResultsSalsalate and young plasma were safe and well tolerated. PSPRS change from baseline (mean ± standard deviation [SD]) was similar in salsalate (+5.6 ± 9.6), young plasma (+5.0 ± 7.1), and historical controls (+5.6 ± 7.1), and change in midbrain volume (cm3 ± SD) did not differ between salsalate (-0.07 ± 0.03), young plasma (-0.06 ± 0.03), and historical controls (-0.06 ± 0.04). No differences were observed between groups on any exploratory endpoint.ConclusionsNeither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.
- Published
- 2020
23. Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease
- Author
-
Cholerton, Brenna, Poston, Kathleen L, Tian, Lu, Quinn, Joseph F, Chung, Kathryn A, Hiller, Amie L, Hu, Shu‐Ching, Specketer, Krista, Montine, Thomas J, Edwards, Karen L, and Zabetian, Cyrus P
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Brain Disorders ,Aging ,Clinical Research ,Dementia ,Rehabilitation ,Acquired Cognitive Impairment ,Neurodegenerative ,Parkinson's Disease ,Basic Behavioral and Social Science ,Behavioral and Social Science ,Mental health ,Neurological ,Activities of daily living ,Parkinson's disease ,cognition ,dementia ,mild cognitive impairment ,study partner ,Clinical sciences - Abstract
IntroductionCognitive dysfunction is common in Parkinson's disease (PD) and associated with reduced functional abilities and increased dependence. To date, however, little is known about the relationship between performance of instrumental activities of daily living (IADLs) and cognitive stages in PD, and there are conflicting reports as to whether declines in specific cognitive domains predict IADL impairment.MethodsParticipants with PD were drawn from the Pacific Udall Center and included in the study if both participant and study partner IADL ratings and cognitive tests were completed (n = 192). Logistic regression analyses were performed to determine whether participant and/or study partner rating predicted mild cognitive impairment or dementia. Correlations are reported for the relationship between participant/study partner IADL reports as well as for specific cognitive tests.ResultsAlthough both participant and study partner ratings of IADL performance were associated with a diagnosis of PD with dementia, only participant self-rating of functional ability was significantly associated with a diagnosis of PD with mild cognitive impairment. Functional ability correlated most strongly with measures of processing speed, auditory working memory, and immediate verbal recall for both the participant and study partner ratings.ConclusionFor participants with PD in the early stages of cognitive decline, self-rating may be more sensitive to the impact of cognitive changes on IADL function than ratings made by a knowledgeable study partner. Changes in executive function, processing speed, and learning may indicate a higher likelihood of IADL impairment. Careful assessment of cognition and IADL performance is recommended to permit individualized interventions prior to significant disability.
- Published
- 2020
24. Hallucinations and Development of Dementia in Parkinson's Disease.
- Author
-
Gryc, Wojciech, Roberts, Kathryn A, Zabetian, Cyrus P, Weintraub, Daniel, Trojanowski, John Q, Quinn, Joseph F, Hiller, Amie L, Chung, Kathryn A, Poston, Kathleen L, Yang, Laurice, Hu, Shu-Ching, Edwards, Karen L, Montine, Thomas J, and Cholerton, Brenna A
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Dementia ,Brain Disorders ,Aging ,Mental Health ,Clinical Trials and Supportive Activities ,Acquired Cognitive Impairment ,Clinical Research ,Neurodegenerative ,Parkinson's Disease ,Neurological ,Aged ,Behavioral Symptoms ,Cognitive Dysfunction ,Cross-Sectional Studies ,Female ,Hallucinations ,Humans ,Longitudinal Studies ,Male ,Middle Aged ,Parkinson Disease ,Behavioral symptoms ,cognition ,dementia ,hallucinations ,Parkinson's disease ,Parkinson’s disease ,Biochemistry and Cell Biology - Abstract
Neuropsychiatric symptoms are common in Parkinson's disease (PD). We investigated the relationship between neuropsychiatric symptoms and current and future diagnosis of PD dementia (PDD). Individuals with PD who had a study partner were enrolled (n = 696). Study partners were administered the Neuropsychiatric Inventory or Neuropsychiatric Inventory Questionnaire at baseline. Participants were assigned a cognitive diagnosis at baseline and follow up visits. Hallucinations were significantly associated with a diagnosis of PDD cross-sectionally (p
- Published
- 2020
25. Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease
- Author
-
Martini, Douglas N, Morris, Rosie, Kelly, Valerie E, Hiller, Amie, Chung, Kathryn A, Hu, Shu-Ching, Zabetian, Cyrus P, Oakley, John, Poston, Kathleen, Mata, Ignacio F, Edwards, Karen L, Lapidus, Jodi A, Grabowski, Thomas J, Montine, Thomas J, Quinn, Joseph F, and Horak, Fay
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Clinical Sciences ,Neurosciences ,Psychology ,Clinical Research ,Genetics ,Parkinson's Disease ,Aging ,Neurodegenerative ,Brain Disorders ,Neurological ,short-latency afferent inhibition ,SAI ,postural sway ,balance ,gait ,GBA ,APOE ,Clinical sciences ,Biological psychology - Abstract
Background: Mobility and sensorimotor inhibition impairments are heterogeneous in Parkinson's disease (PD). Genetics may contribute to this heterogeneity since the apolipoprotein (APOE) ε4 allele and glucocerebrosidase (GBA) gene variants have been related to mobility impairments in otherwise healthy older adult (OA) and PD cohorts. The purpose of this study is to determine if APOE or GBA genetic status affects sensorimotor inhibition and whether the relationship between sensorimotor inhibition and mobility differs in genetic sub-groups of PD. Methods: Ninety-three participants with idiopathic PD (53 non-carriers; 23 ε4 carriers; 17 GBA variants) and 72 OA (45 non-carriers; 27 ε4 carriers) had sensorimotor inhibition characterized by short-latency afferent inhibition. Mobility was assessed in four gait domains (pace/turning, rhythm, trunk, variability) and two postural sway domains (area/jerkiness and velocity) using inertial sensors. Results: Sensorimotor inhibition was worse in the PD than OA group, with no effect of genetic status. Gait pace/turning was slower and variability was higher (p < 0.01) in PD compared to OA. Postural sway area/jerkiness (p < 0.01) and velocity (p < 0.01) were also worse in the PD than OA group. Genetic status was not significantly related to any gait or postural sway domain. Sensorimotor inhibition was significantly correlated with gait variability (r = 0.27; p = 0.02) and trunk movement (r = 0.23; p = 0.045) in the PD group. In PD non-carriers, sensorimotor inhibition related to variability (r = 0.35; p = 0.010) and trunk movement (r = 0.31; p = 0.025). In the PD ε4 group, sensorimotor inhibition only related to rhythm (r = 0.47; p = 0.024), while sensorimotor inhibition related to pace/turning (r = -0.49; p = 0.046) and rhythm (r = 0.59; p = 0.013) in the PD GBA group. Sensorimotor inhibition was significantly correlated with gait pace/turning (r = -0.27; p = 0.04) in the OA group. There was no relationship between sensorimotor inhibition and postural sway. Conclusion: ε4 and GBA genetic status did not affect sensorimotor inhibition or mobility impairments in this PD cohort. However, worse sensorimotor inhibition was associated with gait variability in PD non-carriers, but with gait rhythm in PD ε4 carriers and with gait rhythm and pace in PD with GBA variants. Impaired sensorimotor inhibition had a larger effect on mobility in people with PD than OA and affected different domains of mobility depending on genetic status.
- Published
- 2020
26. Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau
- Author
-
Digma, Leonardino A, Madsen, John R, Rissman, Robert A, Jacobs, Diane M, Brewer, James B, Banks, Sarah J, Weiner, Michael, Aisen, Paul, Petersen, Ronald, Jack, Clifford R, Jagust, William, Trojanowki, John Q, Toga, Arthur W, Beckett, Laurel, Green, Robert C, Saykin, Andrew J, Morris, John, Shaw, Leslie M, Liu, Enchi, Montine, Tom, Thomas, Ronald G, Donohue, Michael, Walter, Sarah, Gessert, Devon, Sather, Tamie, Jiminez, Gus, Harvey, Danielle, Bernstein, Matthew, Fox, Nick, Thompson, Paul, Schuff, Norbert, DeCArli, Charles, Borowski, Bret, Gunter, Jeff, Senjem, Matt, Vemuri, Prashanthi, Jones, David, Kantarci, Kejal, Ward, Chad, Koeppe, Robert A, Foster, Norm, Reiman, Eric M, Chen, Kewei, Mathis, Chet, Landau, Susan, Cairns, Nigel J, Householder, Erin, Reinwald, Lisa Taylor, Lee, Virginia, Korecka, Magdalena, Figurski, Michal, Crawford, Karen, Neu, Scott, Foroud, Tatiana M, Potkin, Steven, Shen, Li, Kelley, Faber, Kim, Sungeun, Nho, Kwangsik, Kachaturian, Zaven, Frank, Richard, Snyder, Peter J, Molchan, Susan, Kaye, Jeffrey, Quinn, Joseph, Lind, Betty, Carter, Raina, Dolen, Sara, Schneider, Lon S, Pawluczyk, Sonia, Beccera, Mauricio, Teodoro, Liberty, Spann, Bryan M, Brewer, James, Vanderswag, Helen, Fleisher, Adam, Heidebrink, Judith L, Lord, Joanne L, Mason, Sara S, Albers, Colleen S, Knopman, David, Johnson, Kris, Doody, Rachelle S, Meyer, Javier Villanueva, Chowdhury, Munir, Rountree, Susan, Dang, Mimi, Stern, Yaakov, Honig, Lawrence S, Bell, Karen L, Ances, Beau, Morris, John C, Carroll, Maria, Leon, Sue, Mintun, Mark A, Schneider, Stacy, and Oliver, Angela
- Subjects
Biological Psychology ,Psychology ,Brain Disorders ,Neurodegenerative ,Alzheimer's Disease ,Neurosciences ,Acquired Cognitive Impairment ,Women's Health ,Aging ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Dementia ,Clinical Research ,tau ,verbal memory ,sex differences ,Alzheimer's disease ,Alzheimer’s Disease Neuroimaging Initiative ,Alzheimer’s disease ,Clinical sciences ,Biological psychology - Abstract
In this study, we aimed to assess whether women are able to withstand more tau before exhibiting verbal memory impairment. Using data from 121 amyloid-β-positive Alzheimer's Disease Neuroimaging Initiative participants, we fit a linear model with Rey Auditory Verbal Learning Test score as the response variable and tau-PET standard uptake value ratio as the predictor and took the residuals as an estimate of verbal memory reserve for each subject. Women demonstrated higher reserve (i.e. residuals), whether the Learning (t = 2.78, P = 0.006) or Delay (t = 2.14, P = 0.03) score from the Rey Auditory Verbal Learning Test was used as a measure of verbal memory ability. To validate these findings, we examined 662 National Alzheimer's Coordinating Center participants with a C2/C3 score (Consortium to Establish a Registry for Alzheimer's Disease) at autopsy. We stratified our National Alzheimer's Coordinating Center sample into Braak 1/2, Braak 3/4 and Braak 5/6 subgroups. Within each subgroup, we compared Logical Memory scores between men and women. Men had worse verbal memory scores within the Braak 1/2 (Logical Memory Immediate: β = -5.960 ± 1.517, P
- Published
- 2020
27. Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease
- Author
-
Morris, Rosie, Martini, Douglas N, Smulders, Katrijn, Kelly, Valerie E, Zabetian, Cyrus P, Poston, Kathleen, Hiller, Amie, Chung, Kathryn A, Yang, Laurice, Hu, Shu-Ching, Edwards, Karen L, Cholerton, Brenna, Grabowski, Thomas J, Montine, Thomas J, Quinn, Joseph F, and Horak, Fay
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Clinical Sciences ,Neurosciences ,Psychology ,Parkinson's Disease ,Aging ,Brain Disorders ,Clinical Research ,Behavioral and Social Science ,Neurodegenerative ,Underpinning research ,1.1 Normal biological development and functioning ,Neurological ,Aged ,Cognition ,Cognitive Dysfunction ,Female ,Gait ,Gait Disorders ,Neurologic ,Humans ,Male ,Middle Aged ,Parkinson Disease ,Postural Balance ,Balance ,Neurological disease ,Cognitive Sciences ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
IntroductionGait and balance impairments are cardinal features of Parkinson's disease (PD) that require cognitive input. However, the extent to which specific gait and balance characteristics relate to cognition in PD is unclear. In addition, independent models of gait and balance have not been developed from the same cohort. We aimed to i) develop models of gait and balance in a large PD cohort and ii) determine which gait and balance characteristics best related to cognition.MethodsOne hundred and ninety-eight people with PD were recruited to the Pacific Udall Center. Using six inertial sensors (APDM, Inc.), comprehensive gait measurements were collected over a 2-min continuous walk and comprehensive static balance measures were collected during a 60-second standing task. Six domains of cognition were assessed: global cognition, attention, executive function, language, memory, and visuospatial function. Correlations and hierarchical linear regression determined independent associations.ResultsPrincipal components analysis identified a gait model containing four domains accounting for 80.1% of total variance: pace/turning, rhythm, variability, and trunk. The balance model contained four independent domains accounting for 84.5% of total variance: sway area/jerkiness, sway velocity, sway frequency anteroposterior, and sway frequency mediolateral. Gait domains of pace/turning and variability were strongly associated with attention and executive function. Sway area and jerkiness of balance associated with attention and visuospatial function.ConclusionsGait and balance characteristics were associated with specific types of cognition. The specific relationships between gait or balance with cognitive functions suggests shared cerebral cortical circuitry for mobility and cognitive functions.
- Published
- 2019
28. Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings
- Author
-
Peterson, Bethany, Armstrong, Melissa, Galasko, Douglas, Galvin, James E, Goldman, Jennifer, Irwin, David, Paulson, Henry, Kaufer, Daniel, Leverenz, James, Lunde, Angela, McKeith, Ian G, Siderowf, Andrew, Taylor, Angela, Amodeo, Katherine, Barrett, Matt, Domoto-Reilly, Kimiko, Duda, John, Gomperts, Stephen, Graff-Radford, Neill, Holden, Samantha, Honig, Lawrence, Huddleston, Daniel, Lippa, Carol, Litvan, Irene, Manning, Carol, Marder, Karen, Moussa, Charbel, Onyike, Chiadi, Pagan, Fernando, Pantelyat, Alexander, Pelak, Victoria, Poston, Kathleen, Quinn, Joseph, Richard, Irene, Rosenthal, Liana S, Sabbagh, Marwan, Scharre, Douglas, Sha, Sharon, Shill, Holly, Torres-Yaghi, Yasar, Christie, Tina, Graham, Todd, Richards, Ian, Koehler, Mike, and Boeve, Brad
- Subjects
Health Services and Systems ,Health Sciences ,Dementia ,Alzheimer's Disease ,Prevention ,Brain Disorders ,Neurosciences ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Neurodegenerative ,Parkinson's Disease ,Alzheimer's Disease Related Dementias (ADRD) ,Clinical Research ,Aging ,Acquired Cognitive Impairment ,Lewy Body Dementia ,Neurological ,Biomedical Research ,Clinical Trials as Topic ,Congresses as Topic ,Humans ,Lewy Body Disease ,New Orleans ,Lewy body dementia ,Lewy Body Dementia Association ,Parkinson's disease dementia ,Parkinson’s disease dementia ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator's meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals, and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new therapeutics.
- Published
- 2019
29. Listen to the voices from the sea: Writings of the fallen Japanese students
- Author
-
Yamanouchi, Midori and Quinn, Joseph L.
- Subjects
BOOK REVIEWS - Published
- 2000
30. Fluoro‐Ethylene‐Carbonate Plays a Double‐Edged Role on the Stability of Si Anode‐based Rechargeable Batteries during Cycling and Calendar Aging
- Author
-
Quinn, Joseph, primary, Kim, Ju‐Myung, additional, Yi, Ran, additional, Zhang, Ji‐Guang, additional, Xiao, Jie, additional, and Wang, Chongmin, additional
- Published
- 2024
- Full Text
- View/download PDF
31. Understanding and Enhancing Silicon Nanoparticle Distribution during Electrode Processing
- Author
-
Wu, Bingbin, primary, Quinn, Joseph P, additional, Li, Jingnan, additional, Li, Qiuyan, additional, Liu, Dianying, additional, Martin, Witness, additional, Baar, Kevin, additional, Zhong, Lirong, additional, Wang, Chongming, additional, and Xiao, Jie, additional
- Published
- 2024
- Full Text
- View/download PDF
32. Cusp shapes of Hilbert-Blumenthal surfaces
- Author
-
Quinn, Joseph and Verjovsky, Alberto
- Subjects
Mathematics - Geometric Topology ,Mathematics - Number Theory ,11F41, 57N16, 11R04 - Abstract
We introduce a new fundamental domain for the cusp stabilizer of a Hilbert modular group over a real quadratic field K=Q(sqrt n). This is constructed as the union of Dirichlet domains for the maximal unipotent group, over the leaves in a foliation of the biplane. The region is the Cartesian product of the positive reals with a 3-dimensional tower formed by deformations of lattices in the ring of integers of K, and makes explicit the cusp cross section's Sol 3-manifold structure and Anosov diffeomorphism. We include computer generated images and data illustrating various examples., Comment: 17 pages, 4 figures, 2 tables
- Published
- 2017
- Full Text
- View/download PDF
33. Retention of Alzheimer Disease Research Participants
- Author
-
Grill, Joshua D, Kwon, Jimmy, Teylan, Merilee A, Pierce, Aimee, Vidoni, Eric D, Burns, Jeffrey M, Lindauer, Allison, Quinn, Joseph, Kaye, Jeff, Gillen, Daniel L, and Nan, Bin
- Subjects
Biomedical and Clinical Sciences ,Biological Psychology ,Clinical Sciences ,Neurosciences ,Psychology ,HIV/AIDS ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Dementia ,Aging ,Acquired Cognitive Impairment ,Alzheimer's Disease ,Neurodegenerative ,Clinical Research ,Brain Disorders ,Aged ,Alzheimer Disease ,Biomedical Research ,Clinical Trials as Topic ,Female ,Humans ,Male ,Motivation ,Patient Selection ,Surveys and Questionnaires ,missing ,missingness ,dropout ,retention ,attrition ,Cognitive Sciences ,Geriatrics ,Clinical sciences ,Biological psychology - Abstract
IntroductionParticipant retention is important to maintaining statistical power, minimizing bias, and preventing scientific error in Alzheimer disease and related dementias research.MethodsWe surveyed representative investigators from NIH-funded Alzheimer's Disease Research Centers (ADRC), querying their use of retention tactics across 12 strategies. We compared survey results to data from the National Alzheimer's Coordinating Center for each center. We used a generalized estimating equation with independent working covariance model and empirical standard errors to assess relationships between survey results and rates of retention, controlling for participant characteristics.ResultsTwenty-five (83%) responding ADRCs employed an average 42 (SD=7) retention tactics. In a multivariable model that accounted for participant characteristics, the number of retention tactics used by a center was associated with participant retention (odds ratio=1.68, 95% confidence interval: 1.42, 1.98; P
- Published
- 2019
34. Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson’s disease
- Author
-
Specketer, Krista, Zabetian, Cyrus P, Edwards, Karen L, Tian, Lu, Quinn, Joseph F, Peterson-Hiller, Amie L, Chung, Kathryn A, Hu, Shu-Ching, Montine, Thomas J, and Cholerton, Brenna A
- Subjects
Biological Psychology ,Psychology ,Neurodegenerative ,Acquired Cognitive Impairment ,Brain Disorders ,Basic Behavioral and Social Science ,Aging ,Mental Health ,Clinical Research ,Behavioral and Social Science ,Neurosciences ,Parkinson's Disease ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Activities of Daily Living ,Aged ,Agnosia ,Executive Function ,Female ,Hallucinations ,Humans ,Male ,Middle Aged ,Neuropsychological Tests ,Parkinson Disease ,Psychometrics ,Quality of Life ,Sleep Wake Disorders ,cognition ,neuropsychological assessment ,Parkinson's disease ,Parkinson’s disease ,Cognitive Sciences ,Experimental Psychology ,Biological psychology ,Clinical and health psychology ,Cognitive and computational psychology - Abstract
Introduction: Cognitive impairment is a common symptom of Parkinson's disease (PD) associated with reduced quality of life and a more severe disease state. Previous research has shown an association between visuospatial dysfunction and worse disease course; however, it is not clear whether this is separable from executive dysfunction and/or dementia. This study sought to determine whether distinct cognitive factors could be measured in a large PD cohort, and if those factors were differentially associated with other PD-related features, specifically to provide insight into visuospatial dysfunction. Methods: Non-demented participants with PD from the Pacific Udall Center were enrolled (n = 197). Co-participants (n = 104) completed questionnaires when available. Principal components factor analysis (PCFA) was utilized to group the neuropsychological test scores into independent factors by considering those with big factor loading (≥.40). Linear and logistic regression analyses were performed to examine the relationship between the cognitive factors identified in the PCFA and other clinical features of PD. Results: Six factors were extracted from the PCFA: 1) executive/processing speed, 2) visual learning & memory/visuospatial, 3) auditory working memory, 4) contextual verbal memory, 5) semantic learning & memory, and 6) visuospatial. Motor severity (p = 0.001), mood (p
- Published
- 2019
35. The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research
- Author
-
Das, Saumya, Consortium, The Extracellular RNA Communication, Abdel-Mageed, Asim B, Adamidi, Catherine, Adelson, P David, Akat, Kemal M, Alsop, Eric, Ansel, K Mark, Arango, Jorge, Aronin, Neil, Avsaroglu, Seda Kilinc, Azizian, Azadeh, Balaj, Leonora, Ben-Dov, Iddo Z, Bertram, Karl, Bitzer, Markus, Blelloch, Robert, Bogardus, Kimberly A, Breakefield, Xandra Owens, Calin, George A, Carter, Bob S, Charest, Al, Chen, Clark C, Chitnis, Tanuja, Coffey, Robert J, Courtright-Lim, Amanda, Datta, Amrita, DeHoff, Peter, Diacovo, Thomas G, Erle, David J, Etheridge, Alton, Ferrer, Marc, Franklin, Jeffrey L, Freedman, Jane E, Galas, David J, Galeev, Timur, Gandhi, Roopali, Garcia, Aitor, Gerstein, Mark Bender, Ghai, Vikas, Ghiran, Ionita Calin, Giraldez, Maria D, Goga, Andrei, Gogakos, Tasos, Goilav, Beatrice, Gould, Stephen J, Guo, Peixuan, Gupta, Mihir, Hochberg, Fred, Huang, Bo, Huentelman, Matt, Hunter, Craig, Hutchins, Elizabeth, Jackson, Andrew R, Kalani, M Yashar S, Kanlikilicer, Pinar, Karaszti, Reka Agnes, Van Keuren-Jensen, Kendall, Khvorova, Anastasia, Kim, Yong, Kim, Hogyoung, Kim, Taek Kyun, Kitchen, Robert, Kraig, Richard P, Krichevsky, Anna M, Kwong, Raymond Y, Laurent, Louise C, Lee, Minyoung, L’Etoile, Noelle, Levy, Shawn E, Li, Feng, Li, Jenny, Li, Xin, Lopez-Berestein, Gabriel, Lucero, Rocco, Mateescu, Bogdan, Matin, AC, Max, Klaas EA, McManus, Michael T, Mempel, Thorsten R, Meyer, Cindy, Milosavljevic, Aleksandar, Mondal, Debasis, Mukamal, Kenneth Jay, Murillo, Oscar D, Muthukumar, Thangamani, Nickerson, Deborah A, O’Donnell, Christopher J, Patel, Dinshaw J, Patel, Tushar, Patton, James G, Paul, Anu, Peskind, Elaine R, Phelps, Mitch A, Putterman, Chaim, Quesenberry, Peter J, Quinn, Joseph F, Raffai, Robert L, and Ranabothu, Saritha
- Subjects
Genetics ,Biomarkers ,Cell-Free Nucleic Acids ,Extracellular Vesicles ,Humans ,Knowledge Bases ,MicroRNAs ,RNA ,Extracellular RNA Communication Consortium ,Biological Sciences ,Medical and Health Sciences ,Developmental Biology - Abstract
The Extracellular RNA Communication Consortium (ERCC) was launched to accelerate progress in the new field of extracellular RNA (exRNA) biology and to establish whether exRNAs and their carriers, including extracellular vesicles (EVs), can mediate intercellular communication and be utilized for clinical applications. Phase 1 of the ERCC focused on exRNA/EV biogenesis and function, discovery of exRNA biomarkers, development of exRNA/EV-based therapeutics, and construction of a robust set of reference exRNA profiles for a variety of biofluids. Here, we present progress by ERCC investigators in these areas, and we discuss collaborative projects directed at development of robust methods for EV/exRNA isolation and analysis and tools for sharing and computational analysis of exRNA profiling data.
- Published
- 2019
36. Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale‐2 in Parkinson's disease
- Author
-
Hendershott, Taylor R, Zhu, Delphine, Llanes, Seoni, Zabetian, Cyrus P, Quinn, Joseph, Edwards, Karen L, Leverenz, James B, Montine, Thomas, Cholerton, Brenna, and Poston, Kathleen L
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Dementia ,Acquired Cognitive Impairment ,Neurodegenerative ,Parkinson's Disease ,Brain Disorders ,Clinical Research ,Aging ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Neurological ,Aged ,Cognition ,Cognition Disorders ,Cognitive Dysfunction ,Female ,Humans ,Male ,Mental Status and Dementia Tests ,Middle Aged ,Neuropsychological Tests ,Parkinson Disease ,Sensitivity and Specificity ,cognitive impairment ,Mattis Dementia Rating Scale-2 ,Montreal Cognitive Assessment ,Parkinson's disease ,Human Movement and Sports Sciences ,Neurology & Neurosurgery ,Clinical sciences - Abstract
BackgroundClinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD.MethodsThe Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521).ResultsThe Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%).ConclusionThe Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD. © 2018 International Parkinson and Movement Disorder Society.
- Published
- 2019
37. Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures.
- Author
-
Kim, Hojoong M, Nazor, Carter, Zabetian, Cyrus P, Quinn, Joseph F, Chung, Kathryn A, Hiller, Amie L, Hu, Shu-Ching, Leverenz, James B, Montine, Thomas J, Edwards, Karen L, and Cholerton, Brenna
- Subjects
Parkinson’s disease ,dementia ,longitudinal ,mild cognitive impairment ,Clinical Research ,Brain Disorders ,Prevention ,Dementia ,Aging ,Parkinson's Disease ,Neurodegenerative ,Acquired Cognitive Impairment ,Neurosciences ,4.2 Evaluation of markers and technologies ,2.1 Biological and endogenous factors ,Neurological - Abstract
Introduction:Cognitive impairment is a common complication of Parkinson's disease (PD) and identifying risk factors for progression to Parkinson's disease dementia (PDD) is important. However, little research has been done comparing the utility of commonly used cognitive screening tests in predicting cognitive progression in PD. Methods:We retrospectively reviewed data from patients with PD enrolled in the Pacific Udall Center who had baseline and longitudinal neuropsychological and global cognitive screening tests. The diagnostic accuracies of 3 common screening tests were compared: Montreal Cognitive Assessment (MoCA), Mattis Dementia Rating Scale (DRS-2), and Mini Mental Status Examination (MMSE). Cognitive diagnoses of PD with mild cognitive impairment (PD-MCI) and PDD were based on full neuropsychological testing and established Movement Disorder Society criteria. Logistic regression and Cox proportional hazards regression models were used to examine predictors of cognitive decline. Results:Four hundred seventy patients for whom scores on all 3 screening tests were available from the same assessment were included in a cross-sectional analysis. The MoCA demonstrated the best overall diagnostic accuracy for PD-MCI (AUC= 0.79, sensitivity= 76.4%) and for PDD (AUC= 0.89, sensitivity= 81.0%) compared to the DRS-2 and MMSE. A longitudinal analysis was performed on the subset of patients (316/470; 67.2%) who were nondemented at baseline and had undergone two or more assessments. After controlling for covariates, the MoCA was the only test associated with progression to PDD (OR= 1.27 95% CI 1.1 - 1.5, p=0.001) and faster time to dementia (HR = 1.3, 95% CI 1.1 - 1.4, p
- Published
- 2019
38. Elevated spermidine serum levels in mild cognitive impairment, a potential biomarker of progression to Alzheimer dementia, a pilot study
- Author
-
Sternberg, Zohara, Podolsky, Rebecca, Nir, Adam, Yu, Jihnhee, Nir, Raphael, Halvorsen, Stanley W, Quinn, Joseph F., Kaye, Jeffrey, and Kolb, Channa
- Published
- 2022
- Full Text
- View/download PDF
39. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
- Author
-
Wilson, Edward N., Young, Christina B., Ramos Benitez, Javier, Swarovski, Michelle S., Feinstein, Igor, Vandijck, Manu, Le Guen, Yann, Kasireddy, Nandita M., Shahid, Marian, Corso, Nicole K., Wang, Qian, Kennedy, Gabriel, Trelle, Alexandra N., Lind, Betty, Channappa, Divya, Belnap, Malia, Ramirez, Veronica, Skylar-Scott, Irina, Younes, Kyan, Yutsis, Maya V., Le Bastard, Nathalie, Quinn, Joseph F., van Dyck, Christopher H., Nairn, Angus, Fredericks, Carolyn A., Tian, Lu, Kerchner, Geoffrey A., Montine, Thomas J., Sha, Sharon J., Davidzon, Guido, Henderson, Victor W., Longo, Frank M., Greicius, Michael D., Wagner, Anthony D., Wyss-Coray, Tony, Poston, Kathleen L., Mormino, Elizabeth C., and Andreasson, Katrin I.
- Published
- 2022
- Full Text
- View/download PDF
40. A Complex Quaternion Model for Hyperbolic 3-Space
- Author
-
Quinn, Joseph A.
- Subjects
Mathematics - Geometric Topology ,Mathematics - History and Overview - Abstract
In 1900, Macfarlane proposed a hyperbolic variation on Hamilton's quaternions that closely resembles Minkowski spacetime. Viewing this in a modern context, we expand upon Macfarlane's idea and develop a model for real hyperbolic 3-space in which both points and isometries are expressed as complex quaternions, analogous to Hamilton's famous theorem on Euclidean rotations. We use this to give new computational tools for studying isometries of hyperbolic 2- and 3-space. We also give a generalization to other quaternion algebras., Comment: 14 pages, 2 figures
- Published
- 2017
41. Macfarlane Hyperbolic 3-Manfiolds
- Author
-
Quinn, Joseph A.
- Subjects
Mathematics - Geometric Topology - Abstract
We identify and study a class of hyperbolic 3-manifolds (which we call Macfarlane manifolds) whose quaternion algebras admit a geometric interpretation analogous to Hamilton's classical model for Euclidean rotations. We characterize these manifolds arithmetically, and show that infinitely many commensurability classes of them arise in diverse topological and arithmetic settings. We then use this perspective to introduce a new method for computing their Dirichlet domains. We also give similar results for a class of hyperbolic surfaces and explore their occurrence as subsurfaces of Macfarlane manifolds., Comment: 22 pages, 4 figures, 1 table
- Published
- 2017
- Full Text
- View/download PDF
42. The Time Course of Changes in Prefrontal Cortex Activity During Walking in People With Parkinson's Disease.
- Author
-
Silva-Batista, Carla, Liu, William, Vitorio, Rodrigo, Stuart, Samuel, Quinn, Joseph F., and Mancini, Martina
- Published
- 2024
- Full Text
- View/download PDF
43. Cultural reproduction of mental illness stigma and stereotypes
- Author
-
Jacobs, Susan and Quinn, Joseph
- Published
- 2022
- Full Text
- View/download PDF
44. Analysis of shared heritability in common disorders of the brain
- Author
-
Consortium, The Brainstorm, Anttila, Verneri, Bulik-Sullivan, Brendan, Finucane, Hilary K, Walters, Raymond K, Bras, Jose, Duncan, Laramie, Escott-Price, Valentina, Falcone, Guido J, Gormley, Padhraig, Malik, Rainer, Patsopoulos, Nikolaos A, Ripke, Stephan, Wei, Zhi, Yu, Dongmei, Lee, Phil H, Turley, Patrick, Grenier-Boley, Benjamin, Chouraki, Vincent, Kamatani, Yoichiro, Berr, Claudine, Letenneur, Luc, Hannequin, Didier, Amouyel, Philippe, Boland, Anne, Deleuze, Jean-François, Duron, Emmanuelle, Vardarajan, Badri N, Reitz, Christiane, Goate, Alison M, Huentelman, Matthew J, Kamboh, M Ilyas, Larson, Eric B, Rogaeva, Ekaterina, St George-Hyslop, Peter, Hakonarson, Hakon, Kukull, Walter A, Farrer, Lindsay A, Barnes, Lisa L, Beach, Thomas G, Demirci, F Yesim, Head, Elizabeth, Hulette, Christine M, Jicha, Gregory A, Kauwe, John SK, Kaye, Jeffrey A, Leverenz, James B, Levey, Allan I, Lieberman, Andrew P, Pankratz, Vernon S, Poon, Wayne W, Quinn, Joseph F, Saykin, Andrew J, Schneider, Lon S, Smith, Amanda G, Sonnen, Joshua A, Stern, Robert A, Van Deerlin, Vivianna M, Van Eldik, Linda J, Harold, Denise, Russo, Giancarlo, Rubinsztein, David C, Bayer, Anthony, Tsolaki, Magda, Proitsi, Petra, Fox, Nick C, Hampel, Harald, Owen, Michael J, Mead, Simon, Passmore, Peter, Morgan, Kevin, Nöthen, Markus M, Schott, Jonathan M, Rossor, Martin, Lupton, Michelle K, Hoffmann, Per, Kornhuber, Johannes, Lawlor, Brian, McQuillin, Andrew, Al-Chalabi, Ammar, Bis, Joshua C, Ruiz, Agustin, Boada, Mercè, Seshadri, Sudha, Beiser, Alexa, Rice, Kenneth, van der Lee, Sven J, De Jager, Philip L, Geschwind, Daniel H, Riemenschneider, Matthias, Riedel-Heller, Steffi, Rotter, Jerome I, Ransmayr, Gerhard, Hyman, Bradley T, Cruchaga, Carlos, Alegret, Montserrat, Winsvold, Bendik, Palta, Priit, Farh, Kai-How, and Cuenca-Leon, Ester
- Subjects
Biological Sciences ,Genetics ,Biological Psychology ,Health Sciences ,Psychology ,Brain Disorders ,Human Genome ,Clinical Research ,Neurosciences ,Mental Illness ,Mental Health ,2.1 Biological and endogenous factors ,Neurological ,Mental health ,Brain Diseases ,Genetic Variation ,Genome-Wide Association Study ,Humans ,Mental Disorders ,Phenotype ,Quantitative Trait ,Heritable ,Risk Factors ,Brainstorm Consortium ,General Science & Technology - Abstract
Disorders of the brain can exhibit considerable epidemiological comorbidity and often share symptoms, provoking debate about their etiologic overlap. We quantified the genetic sharing of 25 brain disorders from genome-wide association studies of 265,218 patients and 784,643 control participants and assessed their relationship to 17 phenotypes from 1,191,588 individuals. Psychiatric disorders share common variant risk, whereas neurological disorders appear more distinct from one another and from the psychiatric disorders. We also identified significant sharing between disorders and a number of brain phenotypes, including cognitive measures. Further, we conducted simulations to explore how statistical power, diagnostic misclassification, and phenotypic heterogeneity affect genetic correlations. These results highlight the importance of common genetic variation as a risk factor for brain disorders and the value of heritability-based methods in understanding their etiology.
- Published
- 2018
45. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
- Author
-
McClain, Kenneth, Picarsic, Jennifer, Chakraborty, Rikhia, Zinn, Daniel, Lin, Howard, Abhyankar, Harshal, Scull, Brooks, Shih, Albert, Lim, Karen, Eckstein, Olive, Lubega, Joseph, Peters, Tricia, Olea, Walter, Burke, Thomas, Ahmed, Nabil, Hicks, M, Tran, Brandon, Jones, Jeremy, Dauser, Robert, Jeng, Michael, Baiocchi, Robert, Goldman, Stanton, Heym, Kenneth, Wilson, Harry, Carcamo, Benjamin, Kumar, Ashish, Rodriguez-Galindo, Carlos, Whipple, Nicholas, Campbell, Patrick, Murdoch, Geoffrey, Kofler, Julia, Heales, Simon, Malone, Marian, Woltjer, Randy, Quinn, Joseph, Orchard, Paul, Kruer, Michael, Jaffe, Ronald, Manz, Markus, Lira, Sergio, Parsons, D, Merad, Miriam, Man, Tsz-Kwong, Allen, Carl, and Schiff, Deborah
- Subjects
BRAF-V600E ,CNS neoplasms ,Langerhans cell histiocytosis ,neurodegeneration ,osteopontin ,Adolescent ,Adult ,Biomarkers ,Biopsy ,Brain ,Brain Neoplasms ,Child ,Child ,Preschool ,Diagnosis ,Differential ,Female ,Hematopoietic Stem Cells ,Histiocytosis ,Langerhans-Cell ,Humans ,Infant ,Infant ,Newborn ,Leukocytes ,Mononuclear ,MAP Kinase Signaling System ,Male ,Neurodegenerative Diseases ,Osteopontin ,Proto-Oncogene Proteins B-raf ,Retrospective Studies ,Young Adult - Abstract
BACKGROUND: Central nervous system Langerhans cell histiocytosis (CNS-LCH) brain involvement may include mass lesions and/or a neurodegenerative disease (LCH-ND) of unknown etiology. The goal of this study was to define the mechanisms of pathogenesis that drive CNS-LCH. METHODS: Cerebrospinal fluid (CSF) biomarkers including CSF proteins and extracellular BRAFV600E DNA were analyzed in CSF from patients with CNS-LCH lesions compared with patients with brain tumors and other neurodegenerative conditions. Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease. RESULTS: Osteopontin was the only consistently elevated CSF protein in patients with CNS-LCH compared with patients with other brain pathologies. BRAFV600E DNA was detected in CSF of only 2/20 (10%) cases, both with LCH-ND and active lesions outside the CNS. However, BRAFV600E+ PBMCs were detected with significantly higher frequency at all stages of therapy in LCH patients who developed LCH-ND. Brain biopsies of patients with LCH-ND demonstrated diffuse perivascular infiltration by BRAFV600E+ cells with monocyte phenotype (CD14+ CD33+ CD163+ P2RY12- ) and associated osteopontin expression. Three of 4 patients with LCH-ND treated with BRAF-V600E inhibitor experienced significant clinical and radiologic improvement. CONCLUSION: In LCH-ND patients, BRAFV600E+ cells in PBMCs and infiltrating myeloid/monocytic cells in the brain is consistent with LCH-ND as an active demyelinating process arising from a mutated hematopoietic precursor from which LCH lesion CD207+ cells are also derived. Therapy directed against myeloid precursors with activated MAPK signaling may be effective for LCH-ND. Cancer 2018;124:2607-20. © 2018 American Cancer Society.
- Published
- 2018
46. Analysis of shared heritability in common disorders of the brain.
- Author
-
Brainstorm Consortium, Anttila, Verneri, Bulik-Sullivan, Brendan, Finucane, Hilary K, Walters, Raymond K, Bras, Jose, Duncan, Laramie, Escott-Price, Valentina, Falcone, Guido J, Gormley, Padhraig, Malik, Rainer, Patsopoulos, Nikolaos A, Ripke, Stephan, Wei, Zhi, Yu, Dongmei, Lee, Phil H, Turley, Patrick, Grenier-Boley, Benjamin, Chouraki, Vincent, Kamatani, Yoichiro, Berr, Claudine, Letenneur, Luc, Hannequin, Didier, Amouyel, Philippe, Boland, Anne, Deleuze, Jean-François, Duron, Emmanuelle, Vardarajan, Badri N, Reitz, Christiane, Goate, Alison M, Huentelman, Matthew J, Kamboh, M Ilyas, Larson, Eric B, Rogaeva, Ekaterina, St George-Hyslop, Peter, Hakonarson, Hakon, Kukull, Walter A, Farrer, Lindsay A, Barnes, Lisa L, Beach, Thomas G, Demirci, F Yesim, Head, Elizabeth, Hulette, Christine M, Jicha, Gregory A, Kauwe, John SK, Kaye, Jeffrey A, Leverenz, James B, Levey, Allan I, Lieberman, Andrew P, Pankratz, Vernon S, Poon, Wayne W, Quinn, Joseph F, Saykin, Andrew J, Schneider, Lon S, Smith, Amanda G, Sonnen, Joshua A, Stern, Robert A, Van Deerlin, Vivianna M, Van Eldik, Linda J, Harold, Denise, Russo, Giancarlo, Rubinsztein, David C, Bayer, Anthony, Tsolaki, Magda, Proitsi, Petra, Fox, Nick C, Hampel, Harald, Owen, Michael J, Mead, Simon, Passmore, Peter, Morgan, Kevin, Nöthen, Markus M, Rossor, Martin, Lupton, Michelle K, Hoffmann, Per, Kornhuber, Johannes, Lawlor, Brian, McQuillin, Andrew, Al-Chalabi, Ammar, Bis, Joshua C, Ruiz, Agustin, Boada, Mercè, Seshadri, Sudha, Beiser, Alexa, Rice, Kenneth, van der Lee, Sven J, De Jager, Philip L, Geschwind, Daniel H, Riemenschneider, Matthias, Riedel-Heller, Steffi, Rotter, Jerome I, Ransmayr, Gerhard, Hyman, Bradley T, Cruchaga, Carlos, Alegret, Montserrat, Winsvold, Bendik, Palta, Priit, Farh, Kai-How, Cuenca-Leon, Ester, and Furlotte, Nicholas
- Subjects
Brainstorm Consortium ,Humans ,Brain Diseases ,Risk Factors ,Mental Disorders ,Quantitative Trait ,Heritable ,Phenotype ,Genetic Variation ,Genome-Wide Association Study ,Clinical Research ,Neurosciences ,Rare Diseases ,Human Genome ,Brain Disorders ,Genetics ,Mental Health ,2.1 Biological and endogenous factors ,Mental health ,Neurological ,General Science & Technology - Abstract
Disorders of the brain can exhibit considerable epidemiological comorbidity and often share symptoms, provoking debate about their etiologic overlap. We quantified the genetic sharing of 25 brain disorders from genome-wide association studies of 265,218 patients and 784,643 control participants and assessed their relationship to 17 phenotypes from 1,191,588 individuals. Psychiatric disorders share common variant risk, whereas neurological disorders appear more distinct from one another and from the psychiatric disorders. We also identified significant sharing between disorders and a number of brain phenotypes, including cognitive measures. Further, we conducted simulations to explore how statistical power, diagnostic misclassification, and phenotypic heterogeneity affect genetic correlations. These results highlight the importance of common genetic variation as a risk factor for brain disorders and the value of heritability-based methods in understanding their etiology.
- Published
- 2018
47. Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease
- Author
-
Cholerton, Brenna, Johnson, Catherine O, Fish, Brian, Quinn, Joseph F, Chung, Kathryn A, Peterson-Hiller, Amie L, Rosenthal, Liana S, Dawson, Ted M, Albert, Marilyn S, Hu, Shu-Ching, Mata, Ignacio F, Leverenz, James B, Poston, Kathleen L, Montine, Thomas J, Zabetian, Cyrus P, and Edwards, Karen L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Aging ,Parkinson's Disease ,Neurodegenerative ,Dementia ,Behavioral and Social Science ,Acquired Cognitive Impairment ,Clinical Research ,Alzheimer's Disease ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Brain Disorders ,Neurosciences ,Neurological ,Adult ,Aged ,Aged ,80 and over ,Cognitive Dysfunction ,Disease Progression ,Female ,Humans ,Longitudinal Studies ,Male ,Middle Aged ,Parkinson Disease ,Sex Characteristics ,Sex Factors ,Parkinson's disease ,Cognition ,Mild cognitive impairment ,Sex differences ,Cognitive Sciences ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
INTRODUCTION:Identification of factors associated with progression of cognitive symptoms in Parkinson's disease (PD) is important for treatment planning, clinical care, and design of future clinical trials. The current study sought to identify whether prediction of cognitive progression is aided by examining baseline cognitive features, and whether this differs according to stage of cognitive disease. METHODS:Participants with PD in the Pacific Udall Center Clinical Consortium who had longitudinal data available and were nondemented at baseline were included in the study (n = 418). Logistic and Cox regression models were utilized to examine the relationship between cognitive, demographic, and clinical variables with risk and time to progression from no cognitive impairment to mild cognitive impairment (PD-MCI) or dementia (PDD), and from PD-MCI to PDD. RESULTS:Processing speed (OR = 1.05, p = 0.009) and working memory (OR = 1.01, p = 0.03) were associated with conversion to PDD among those with PD-MCI at baseline, over and above demographic variables. Conversely, the primary predictive factor in the transition from no cognitive impairment to PD-MCI or PDD was male sex (OR = 4.47, p = 0.004), and males progressed more rapidly than females (p = 0.01). Further, among females with shorter disease duration, progression was slower than for their male counterparts, and poor baseline performance on semantic verbal fluency was associated with shorter time to cognitive impairment in females but not in males. CONCLUSIONS:This study provides evidence for sex differences in the progression to cognitive impairment in PD, while specific cognitive features become more important indicators of progression with impending conversion to PDD.
- Published
- 2018
48. Homocysteine and cognitive function in Parkinson's disease
- Author
-
Licking, Nicole, Murchison, Charles, Cholerton, Brenna, Zabetian, Cyrus P, Hu, Shu-Ching, Montine, Thomas J, Peterson-Hiller, Amie L, Chung, Kathryn A, Edwards, Karen, Leverenz, James B, and Quinn, Joseph F
- Subjects
Clinical and Health Psychology ,Psychology ,Neurosciences ,Parkinson's Disease ,Brain Disorders ,Behavioral and Social Science ,Prevention ,Acquired Cognitive Impairment ,Neurodegenerative ,Aging ,Clinical Research ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Aged ,Antiparkinson Agents ,Cognition ,Cognitive Dysfunction ,Cohort Studies ,Female ,Homocysteine ,Humans ,Male ,Middle Aged ,Neuropsychological Tests ,Parkinson Disease ,Parkinson's disease ,Movement disorders ,Dementia ,Clinical Sciences ,Cognitive Sciences ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
IntroductionIncreased plasma homocysteine (HC) is a risk factor for dementia in the general population. Levodopa therapy causes increased plasma HC, but it remains unclear whether elevated plasma HC is associated with cognitive impairment in Parkinson's disease (PD).MethodsThe study population includes all participants in the Pacific Northwest Udall Center (PANUC) Clinical cohort at the time of the study, consisting of 294 individuals with PD who had a standardized neuropsychological assessment and plasma collection for HC measurement. We tested the hypothesis that elevated plasma HC is inversely related to cognitive function in patients with PD.ResultsAs expected, plasma HC was positively associated with age, disease duration, disease severity, and levodopa usage, while cognitive function was associated with age, education, gender, and APOE genotype, so subsequent analyses controlled for these covariates. When plasma HC was dichotomized as normal (
- Published
- 2017
49. Surface and Bulk Stabilization of Silicon Anodes with Mixed-Multivalent Additives: Ca(TFSI)2 and Mg(TFSI)2
- Author
-
Park, Sohyun, primary, Liu, Haoyu, additional, Quinn, Joseph, additional, Lapidus, Saul H., additional, Zhang, Yunya, additional, Trask, Stephen E., additional, Wang, Chongmin, additional, Key, Baris, additional, and Dogan, Fulya, additional
- Published
- 2024
- Full Text
- View/download PDF
50. Asiatic acid improves mitochondrial function, activates antioxidant response in the mouse brain and improves cognitive function in beta-amyloid overexpressing mice
- Author
-
Varada, Samantha, primary, Chamberlin, Steve R, additional, Bui, Lillie, additional, Brandes, Mikah S, additional, Gladen-Kolarsky, Noah, additional, Harris, Christopher J, additional, Hack, Wyatt, additional, Brumbach, Barbara H, additional, Quinn, Joseph F, additional, and Gray, Nora E, additional
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.